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1. Introduction 
Statins are now among the most frequently prescribed agents for reducing morbidity and 
mortality related to cardiovascular diseases (Figure 1) and analysis of these drugs is a 
current problem. The major therapeutic action of statin drugs is reduction of circulating 
atherogenic lipoproteins as a result of inhibition of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase [1]. The key enzyme catalyzes the conversion of HMG-CoA to 
mevalonate, a critical intermediary in the cholesterol biosynthesis. This mechanism was 
discovered in 1976, when Endo and co-workers isolated a compound mevastatin from 
Penicillium citrinum that exhibited cholesterol-lowering effects [2]. Clinical studies have 
shown that statins significantly reduce the risk of heart attack and death in patients with 
proven coronary artery disease, and can also reduce cardiac events in patients with high 
cholesterol levels [3]. Beside lipid-lowering activity, statins improve endothelial function, 
maintain plaque stability and prevent thrombus formation. There is also an increased 
interest in statins non-lipid activities such as an anti-inflammatory action [4].  
Ischemic heart disease is the leading cause of death in middle- and high-income countries, 
killing over 7 million people each year. Cardiovascular disease has no geographic, gender or 
socio-economic boundaries, and will remain the leading cause of death globally in the 
future. Therefore, the development of new analytical methods for statin drugs is of great 
importance. Analytical methods are employed through entire life cycle of a drug, from 
design and manufacture, elucidating the mechanism of biotransformation, clinical trials, 
dosage scheme adjustment, its introduction into the marketplace, quality control and 
pharmacovigilance to drug recycling and disposal with emphasis on environmental 
protection.  
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Statins can be grouped into fermentation-derived and chemically synthesized. Lovastatin, 
also called mevinolin, was isolated as secondary metabolite of fermentation process of 
various fungi such as Aspergillus terreus, Monascus ruber and Penicillium species [5, 6]. 
Lovastatin was the first commercially available compound for treatment of 
hypercholesterolemia, approved for use in 1987. It is produced biosynthetically from the 
fungus Aspergillus terreus. Whereas lovastatin is a natural product, simvastatin and 
pravastatin are semi-synthetic. Simvastatin is obtained by synthesis from lovastatin by 
replacement of 2-methylbutyryl side chain with 2,2-dimethylbutyryl group, while 
pravastatin is produced by microbial hydroxylation of mevastatin by Strepromyces 
carbophilus. Fluvastatin, atorvastatin, pitavastatin and rosuvastatin are completely synthetic 
compounds. Although all statins share a common mechanism of action and structural 
component that is very similar to the HMG portion of HMG-CoA reductase, they differ in 
terms of their chemical structures (Figure 1). The statins differ from each other in the rigid, 
hydrophobic structures covalently linked to the HMG-like moiety. The naturally derived 
statins contain a substituted decalin ring structure. Only pravastatin has a hydroxyl 
substituent on the hexahydronaphthalene nucleus which causes higher hydrophilicity. Fully 
synthetic statins have fluorophenyl groups linked to the HMG-like moiety. Depending upon 
chemical structure, statins have different affinities for HMG-CoA reductase and different 
pharmacokinetic properties [7]. Clinical trials have demonstrated rosuvastatin to be the 
most effective in reducing LDL cholesterol. In addition to the standard statin 
pharmacophore, rosuvastatin molecule contains a polar methyl sulfonamide group that 
forms a unique interaction with the catalytic site of HMG-CoA reductase. Cerivastatin was a 
synthetic statin drug, approved in 1997. Unfortunately, due to its fatal rhabdomyolysis, as a 
sever side effect, it was voluntarily withdrawn from the market in 2001. 
Statins exist in two forms, lactone and open-ring hydroxy acid forms. Lovastatin and 
simvastatin are administered as lactone prodrugs and subsequently transformed to active 
metabolites in contrast to other statins, which are formulated in the pharmacologically 
active β-hydroxy acid form. In vivo, lactone prodrugs are enzymatically hydrolyzed to their 
hydroxy acid pharmacophores in the liver to achieve pharmacological activity [8]. The 
lactone forms can be converted in aqueous solutions to their corresponding hydroxy acid 
equilibrium products. Such interconversion may occur even in the biological matrix before 
collecting aliquots of the sample, during sample preparation and analysis of the drug. 
Therefore, it is crucial to optimize the multiple steps of the analytical method in order to 
minimize the interconversion during the analysis. On the other hand, statins in β-hydroxy 
acid form possess two hydroxyl groups in an alkyl chain at the β and δ positions with 
respect to the carboxylic acid group. The carboxylic acid group and the hydroxyl group at 
the δ position are prone to lactonize. Therefore, all statins may exist in solutions in the free 
acid form or the lactone form or as an equilibrium mixture of both forms in a pH-dependent 
manner [9]. For samples of hydroxy acid and lactone forms, maintaining the pH of solution 
around 4-5 minimizes interconversion. Increasing the pH above 6 facilitates the conversion 
of lactone to acid, whereas lowering pH enables the conversion from acid to lactone or 
lactone to acid in the non-ionized form. Consequently, great care must be exercised when 
handling these compounds in order to isolate them in high yields and the analytical 
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methods should be designed for the simultaneous quantification of two analytes that can 
potentially undergo interconversion during analysis.  
Statins are considered for long-term therapy and thus the purity assessment of these drugs 
is of great significance. Development of selective methods for monitoring their potential 
impurities and degradation products is highly required. Identification and determination of 
drug-related substances is an important aspect because impurities and degradation 
products of drugs are often responsible for some side-effects. The estimation of the impurity 
profiles of bulk drugs or dosage formulations requires methods involving high sensitivity 
and resolution as well as acceptable analysis time. The hyphenated technique that 
incorporates the efficient separation using liquid chromatography and specific and sensitive 
detection by mass spectrometry has become indispensable tool for identification and 
structure elucidation of unknown impurities in statin drugs as well as quantification of trace 
impurity levels.  
Various chromatographic methods for determination of statins and their related impurities 
in the bulk drug forms and pharmaceutical formulations were developed. Almost all 
methods used for the separation of statins are based on high-performance liquid 
chromatography. In pharmaceutical applications UV detection was most commonly used. 
Analytical methods for determination of statins were developed individually as expected 
from their different structural and chemical properties. This approach to the analysis was 
chosen most probably because statins are not used in combination with other statin 
molecules during therapy. However, the development of a rapid analytical procedure that is 
not limited to the analysis of only one statin can be considered as a very useful assessment 
in quality control. Numerous chromatographic methods for quantification of statins in 
different biological fluids were developed. The levels of statins in biological fluids are very 
low because only about 5% of dosed statin reaches the systematic circulation. The liquid 
chromatography coupled to tandem mass spectrometry has become the method of choice 
for therapeutic plasma level monitoring of statins and their metabolites in pharmacokinetic 
investigations [10]. Generally, hyperlipidemic patients are treated with multiple-drug 
regime which commonly leads to drug interaction. The simultaneous determination of 
statins and drugs usually combined in cardiovasculary therapy in human plasma is 
important to get more insight in their possible interactions with a consequent increased risk 
to toxic effects. Due to different physical and chemical properties of co-administrated drugs 
development of methods for their simultaneous analysis is an over going challenge. 
This chapter will present recent advances in chromatographic and capillary electrophoretic 
methods for the determination of statin drugs in various fields of application. Current 
trends in developing new methods for analysis of the most frequently used drugs will be 
discussed.  
2. Pharmaceutical application  
Pharmaceutical analysis provides information on the identity, purity, content and stability 
of starting material, excipients and active pharmaceutical ingredients (APIs). A distinction is 
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made between analysis of the pure active ingredients and pharmaceutical formulations. 
Specification and test methods for the commonly used API and excipients are described in 
detail in pharmacopoeias. 
Impurity profiling is of great importance in new drug substance and new drug product 
because of their potential unwanted pharmacological effects, possible toxicity, side effects, 
and their eventual impact on the activity, efficacy and the stability of the drug, its 
bioavailability and the results of the drug analysis. International Conference on 
Harmonization (ICH) gives strict regulatory guidelines for identification and quantification 
of trace impurities in drugs. Any compound that does not have the same chemical entity as 
the active substance, present at levels higher than 0.1% or 0.05% (depending on the daily 
dose), needs to be identified. Therefore there is a permanent need for developing new 
accurate, selective, and sensitive methods for the determination of drug impurities. 
Impurities can come from starting materials, they can be intermediars and by-products from 
the synthesis of the API (process related impurities), degradation products formed during 
manufacturing process and long-term storage, interaction products between API and other 
active ingredients and excipients or primary container. 
Stability indicating methods are quantitative test methods that can detect changes of API 
and drug products during time and under certain conditions. Information on type and 
amount of degradation products over time is important for quality, safety and efficacy of the 
drug. Therefore, Food and Drug Administration (FDA), European Medicines Agency and 
other regulatory agencies, along ICH and good manufacturing practise require development 
and validation of stability indicating methods. General purpose of stability testing is to 
provide evidence on how the quality of an API or a finished pharmaceutical product 
changes during time under the influence of different environmental factors such as 
temperature, humidity and light. After these tests have been performed, recommendation 
on storage conditions and shelf life of the product can be given. ICH guidelines give 
detailed description of forced decomposition studies (stress testing). Stress testing of the API 
can help identify possible degradation products. It should include the effect of temperature 
(in 10 °C increments), humidity (≥ 75% relative humidity), oxidation, photolysis and 
hydrolysis of the API at a wide range of pH (acidic, neutral and alkali conditions).  
In this section a review of chromatographic methods applied for identification and 
quantification of statins in bulk drug and pharmaceutical dosage forms will be given (Table 
1). Each statin commercially available on the market will be covered in this review. Special 
emphasis will be given to stability indicating methods and papers describing impurity 
profiling.  
Statins are often manufactured in combined pharmaceutical formulations together with 
ramipril, acetylsalicylic acid, amlodipine etc., and especially ezetimibe, a novel lipid-
lowering agent that inhibits the absorption of cholesterol in the intestine by blocking 
Niemann-Pick C1-like protein cholesterol transporter. A synergic effect in reducing plasma 
concentrations of LDL cholesterol is achieved, mainly by the combination of statin and 
ezetimibe. Since statins are often co-administered with other drugs in therapy of 
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cardiovascular disease, i.e. acetylsalicylic acid, antihypertensive medicines (ACE inhibitors, 
calcium channel blockers), but also in combined therapy of multiple disorders, e.g. 
antidiabetics, diuretics, nonsteroidal anti-inflammatory drugs and other analgetics, 
antibiotics etc.  In order to avoid problems with patient compliance when a combination of 
acetylsalicylic acid, antihypertensives, lipid-lowering drugs and etc. is required, a polypill, a 
fixed-dose combination containing three or more drugs in a single pill, would be the 
solution. Methods describing simultaneous analysis of these combined pharmaceutical 
products will also be mentioned.  
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Figure 1. Chemical structures of statins 
2.1. Lovastatin 
The first statin registered as a drug was lovastatin. Nowadays, in therapy it is greatly 
replaced by new synthetic products, mainly atorvastatin and simvastatin. Therefore there 
are not many new methods for determination and quantification of lovastatin in bulk drug 
and pharmaceutical formulations.  
There are scarce reports investigating the conversion of statins from lactone to their 
corresponding hydroxy acid forms. Yang and Hwang studied the conversion of lovastatin 
and simvastatin from lactone to corresponding hydroxy acid forms [11]. They concluded 
that the conversion of lactone forms to corresponding hydroxy acid forms would occur in 
water or 70% acetonitrile. However, this conversion could be retarded by addition of acetic 
acid to the solution. Hence a mobile phase with acetic acid added to the composition is 
recommended for HPLC analysis. Furthermore, lactone forms could only be transformed to 
their corresponding hydroxy acid forms in 0.1 M NaOH or 0.05 M KOH prepared in 25% or 
50% acetonitrile in water. When alkaline methanolic solutions were used further 
transformation to methyl ester of hydroxy acid form would take place. Recently another 
paper was published investigating conversion of lovastatin [12]. The identity of all three 
forms, lovastatin, lovastatin hydroxy acid and its methyl ester was confirmed by 
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electrospray ionization (ESI) mass spectrometry (MS). Their results imply that also under 
acidic conditions, with increase of storage time, lactone is converted to hydroxy acid form 
and further transformed to methyl ester form.  
Bearing in mind the interconversion problem, special attention should be given to the choice of a 
mobile phase for HPLC analysis, the extraction procedure and sample storage time. Methanol in 
acidic conditions should be avoided because it induces the conversion and transformation of 
lovastatin forms. Hence, most recently developed LC methods utilize pH around 4.5. 
Lovastatin is an active pharmaceutical ingredient in red yeast rice products, used as a 
dietary supplement. In such products lovastatin is mostly refered to as monakolin K, and is 
accompanied by 13 more monacolins naturally occurring in red yeast rice. These products 
are frequently used by millions of people as a complementary and alternative therapy for 
lowering total lipid and LDL cholesterol levels. Unfortunately dietary supplements do not 
follow strict quality control as medicines do, active ingredients are not standardized and 
published on labels, and considerable variations can be found among different 
manufactures even between lots of the same manufacture. Therefore there is a growing need 
for specific and precise methods for determination of lovastatin in red yeast rice dietary 
supplements in order to ensure standardization, efficacy and safety of these products.  
Identification and chemical profiling of all 14 monacolins in red yeast rice and its formulated 
products was conducted using HPLC with photodiode array detecore (PDA) and MS [13]. 
Because red yeast rice has a complex matrix, sample extraction procedure was carried out 
with 75% ethanol. Chemical profiling was performed using electrospray ionization and ion 
trap mass analyzer. Since lovastatin content depends on the fermentation process of the rice 
by Monascus purpureus, an LC-PDA-ESI-ion trap method was published investigating 
differences in raw material powder and finished products [14].  
A stability-indicating method for the stress test of red yeast rice was also performed [15]. An 
assay of seven main monacolins, monacolin K (lovastatin), monacolin J, monacolin L and 
their corresponding hydroxy acid forms and dehydromonacolin K, representing 97% of total 
monacolins, was determined. In order to shorten the analysis time Song et al. proposed a 
fast screening method of lovastatin in red yeast rice products by flow injection tandem mass 
spectrometry without LC separation [16].  
2.2. Simvastatin 
Simvastatin is along atorvastatin the most often used statin drug and there is a great number 
of analytical methods developed. Novakova et al. published a review paper on HPLC 
methods for the determination of simvastatin and atorvastatin [17]. An oversight on 
different areas of application, pharmaceutical formulations, clinical medicine (human 
plasma) and environmental (aqueous samples) was given. A more detailed overview will be 
given on papers not covered by this review. 
A simple HPLC-UV method was optimized according to the USP chromatographic method 
for simvastatin [18]. By changing the column length from 30 cm to a Chromolith RP18 
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monolithic column, 10 cm in length and reducing the pH to 3.0, a reduction in elution time 
was about 60%, resulting in analysis time less than 4 min. Method was applied to determine 
the quality of 60 compounding simvastatin 40 mg capsules. The mean content and weight 
variation evaluation, content uniformity, determination of simvastatin concentration, 
determination of lovastatin as an impurity and the dissolution test were performed. Results 
were devastating. The mean content of the capsules varied from 70 mg to 316 mg. In ten 
Brazilian pharmacies more than one tested capsule was outside the range from 85-115%. 
Only three pharmacies presented content uniformity with values complying to reference 
ones. Capsules from all the pharmacies resulted in simvastatin content less than 100% of the 
declared value. In 6 of them the content ranged from 4-87% of the declared amount. These 
results do not meet the requirements for simvastatin contents, resulting in underdosing. 
These appalling results emphasize the need for the control of raw material, compounding 
process and finished products quality, efficacy and safety.   
Tablet splitting is a somewhat controversial topic among pharmacy practitioners, patients, 
managed care organizations and many other associations involved in health care. However 
it has become increasingly common, especially within geriatric and psychiatry communities. 
There are many concerns surrounding tablet splitting program, mainly if there will be 
considerable weight fluctuations, will the daily dose be the same in two half's, and will 
tablet splitting deliver same clinical outcomes at a lower cost. Hill et al. presented an HPLC-
UV method, taken from the USP monograph and adapted to half-tablets, for drug content 
and weight uniformity for half-tablets of six commonly split medications, including 
simvastatin [19]. There analysis found 38.80 mg as target drug content, while the measured 
drug content mean was 40.06 mg, with a RSD 4.29%. Target drug content ranges from 
95.21% to 111.35%. These small changes in daily dose should have no significant impact on 
long-term clinical end points.  
RP-HPLC method was developed and validated for simultaneous analysis of simvastatin 
and tocotrienol and tocopherols isoforms in simvastatin-tocotrienol nanoparticles 
manufactured as potential targeted therapy of breast cancer [20]. In order to obtain good 
resolution in short analysis time the separation was carried out on a Phenomenex Onyx C18 
monolithic column (100 mm x 4.6 mm) with a gradient elution. 
Preparation and evaluation of a high-dose nicotinic acid loaded sustained-release pellets 
coated with double polymer and immediate release simvastatin was introduced by Zhao 
and co-workers [21]. After the preparation of drug-loaded pellets, drug content analysis was 
performed by HPLC for both nicotinic acid and simvastatin. However, unnecessary, 
different methods, using similar columns and mobile phases, were employed. 
There are a number of methods describing simultaneous determination of simvastatin and 
ezetimibe from their combination drug products [22-25]. Stability indicating studies on 
combined pharmaceutical products of simvastatin and ezetimibe have also been published 
[24, 25]. Different approaches to forced degradation study, chromatographic conditions and 
determination of degradation products were performed. Hefnawy and co-workers proposed 
a very fast and sensitive stability indicating method for simultaneous determination of 
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ezetimibe and simvastatin in tablet dosage form [25]. Instead of traditional chromatographic 
columns packed with porous particles, they used a monolithic stationary phases, i.e. RP 
Merck Chromolith Performance column (RP-18e, 100 mm x 4.6 mm). Due to monolithic 
stationary phase, an elevated flow rate is possible, resulting in a run-time five-fold reduced 
(analysis time under 2 min), consumption of mobile phase about two-fold decreased, while 
the resolution between peaks remained unaffected.   
Several methods have been developed for identification and quantification of known 
impurities, but many also studied fragmentation and structural determination of unknown 
simvastatin impurities [26-29]. Structural characterization and identification of a new 
compound, an unknown simvastatin by-product generated during the industrial synthesis 
starting from lovastatin was published [26]. After HPLC-diode array detector (DAD) 
analysis, ESI-ion trap mass analyzer was employed to obtain MS/MS spectra, followed by 
Fourier transform-infrared spectroscopy (FT-IR) and nuclear magnetic resonance (NMR) 
analysis.  
Plumb et al. [27] proposed a method using high resolution sub 2 μm particle LC column 
together with hybrid quadrupole orthogonal time-of-flight (TOF) mass spectrometer used to 
profile and identify simvastatin impurities. All common impurites were identified in a 
single 10 min run. A new impurity of simvastatin was detected and identified as the 
saturated ring form of simvastatin. The same group published a paper on screening 
pharmaceutical products by ultra performance liquid chromatography (UPLC) coupled to 
TOF-MS [28]. Principal components statistical analysis was used for rapid classification of 
batches of simvastatin tablets according to their impurity profile.  
Reddy et al. [29] performed HPLC separation of simvastatin and its two main impurities, 
anhydro-simvastatin and simvastatin dimmer. An unknown impurity was detected. MS/MS 
spectrum was obtained by ESI+ and ion-trap mass analyzer and the structure of the so far 
unknown simvastatin impurity was proposed. Recently, a paper on synthesis, 
characterization and quantification of simvastatin's metabolites and impurities was 
published [30]. This method emphasizes use of non-compendial reference standards for 
quantification, with shorter analysis time and improved sensitivity. β-hydroxy acid and 
methyl ester of simvastatin were synthesized as non-compendial reference standards. After 
complete and detailed characterization by MS, FT-IR and NMR, they were used as reference 
standards in quantification of simvastatin impurities.  
2.3. Pravastatin 
An HPLC method for quantification of pravastatin in tablets was published [31]. However, 
an unnecessary complicated extraction procedure and linearity investigation was 
performed. Identification of an impurity in pravastatin was performed by application of 
collision-activated decomposition mass spectra both in positive and negative ionization 
mode [32]. The impurity is an analogue of pravastatin with an additional methyl group on 
ester side chain.   
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Two stability indicating studies of pravastatin under different forced degradation conditions 
were conducted [33, 34]. Forced degradation study was performed for neutral, acid and 
basic hydrolysis, chemical oxidation, photochemical degradation and thermal stress using 
HPLC-UV [33]. Under neutral hydrolysis a decrease in the peak area of pravastatin was 
observed accompanied by two additional peaks. In basic hydrolysis a 90% decrease of 
pravastatin peak was noted and an additional peak is obtained, while in acidic conditions 
pravastatin peak completely disappeared and two new signals appeared. Degradation of 
pravastatin was also observed under oxidative conditions, while under thermal stress no 
change was percived.  
Results obtained by Brain-Isasi et al. [34] are somewhat different then those previously 
published [33]. They argue that the previously described method was to short (7 min) to 
observe all degradation peaks obtained by acid hydrolysis while all of them are eluting after 
pravastatin. This indicates they are more liphophyllic than the parent drug, probably 
formed after esterification and lactonization of pravastatin. By the use of MS/MS spectra 
obtained in the positive mode, one of the peaks was identified as pravastatin lactone form. 
In alkaline medium only one product was observed and after preparative TLC it was 
isolated and identified by 1H-NMR and 13C-NMR as the 8-hydroxy derivate of pravastatin. 
2.4. Fluvastatin 
Photodegradation study of fluvastatin has been studied and examined by high-
performance-thin-layer chromatography (HPTLC) and spectrophotometry [35]. 
Photoproducts were separated by HPTLC on a nonpolar C18 stationary phase with a 
mixture of phosphate buffer and methanol as a mobile phase. Both in water and methanol 
solutions, photochemical decomposition led to the formation of three major products.  
2.5. Atorvastatin 
Of all seven statins, atorvastatin is the most often administered statin drug. In fact, it is one 
of the most often prescribed prescription drugs overall. Therefore many methods are 
developed for determination and quantification of atorvastatin in bulk drug and 
pharmaceuticals. Since Novakova et al. in 2008 [17] gave a review of HPLC methods for the 
determination of atorvastatin in pharmaceutical assays, only papers published afterwards 
will be presented.  
There are several stability indicating methods for determination of atorvastatin using 
different techniques and detectors. A RP-HPTLC method using aluminium sheets precoated 
with silica gel 60 RP18F(254) as the mobile phase consisted of methanol-water was used for 
determination of atorvastatin in bulk drug and pharmaceutical formulation [36]. 
Quantification was conducted densitometrically at 246 nm. Under acidic conditions drug 
underwent significant hydrolysis, while it was stable under alkali, oxidation, dry heat and 
photodegradation conditions. HPLC method using fluorescence detector (282 nm excitation, 
400 nm emission) was introduced for analysis of atorvastatin and its degradation products 
in bulk drug and tablet form [37]. HPLC method with UV detection at 247 nm was 
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developed for determination of atorvastatin and its degradation products in bulk drug, 
marketed tablet and in-house prepared nanoemulsion formulation [38].  
Another stability indicating method was proposed for simultaneous determination of 
atorvastatin and amlodipine alongside with their degradation products in commercial 
combined tablets [39]. An UPLC method using ethylene bridged hybrid C18 column (50 mm 
x 2.1 mm, 1.7 μm) was used for simultaneous determination and quantitation of 
atorvastatin, acetylsalicylic acid and their four known and six unknown degradation 
products in combined dosage forms [40].   
Two LC-MS method were reported for structure determination and identification of 
atorvastatin degradation products. An LC method employing an atmospheric pressure 
chemical ionization (APCI) source in positive mode with TOF mass spectrometer for 
acquiring accurate mass and an ion trap analyzer for complete fragmentation pattern was 
introduced [41]. Six unknown atorvastatin degradation products formed under stress 
conditions of hydrolysis, oxidation and photolysis were identified. Preparative HPLC 
method with Luna prep C18(2) column (200 mm x 50 mm, 10 μm) was used for isolation of 
four oxidative degradation products [42]. HPLC coupled to MS, high resolution MS and 
NMR spectroscopy were applied for the structure elucidation. Quantitative NMR 
spectroscopy was used for assay determination of isolated oxidative atorvastatin 
degradation products. A fast UPLC method with analysis time of 3 min was employed for 
determination of atorvastatin, fenofibrate and their degradation products in combined 
dosage forms [43].  
We have developed HPLC/DAD/ESI/MSn method for separation and identification of 
atorvastatin and its four related impurities [44]. To avoid hydrolysis of the atorvastatin 
lactone and the lactonization of acid form, ammonium buffer pH 4.0 was used. In order to 
achieve separation between atorvastatin and its diastereomer, several mobile phases were 
examined. Finally, a gradient elution mode was chosen to achieve good separation between 
peaks adjacent to the drug components, as well as to keep short analysis time of lipophilic 
impurities (Fig. 2.). Mass spectra were obtained by ESI source in the positive ion mode and 
ion trap analyzer. For quantitative analysis of atorvastatin and its four known impurities 
multiple reaction monitoring (MRM) mode was employed. Several unknown impurities 
were identified through MS/MS fragmentation analysis, i.e. diamino-atorvastatin, photolytic 
oxo-product, photolytic degradation product and diastereomer of atorvastatin lactone. 
Method was successfully applied to bulk drug and pharmaceutical dosage forms provided 
by different manufactures (Figure 2).  
HPLC-UV method was developed for simultaneous determination of atorvastatin and seven 
related compounds specified as process-related impurities and possible degradation 
impurities. Experimental design was used during method optimization and robustness 
testing [45]. Artificial Neural Networks were used for the modelling and prediction of 
chromatographic retention of atorvastatin and its impurities in micellar liquid 
chromatography [46].  
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Atorvastatin in combined dosage forms, e.g. with ezetimibe, fenofibrate, ramiprile was 
determined by HPTLC methods [47, 48]. HPLC methods were published for simultaneous 
determination of atorvastatin in combination with amlodipin [49], fenofibrate [50], ezetimibe 
[51] and ramiprile [47, 52]. An improved HPLC method, with higher sensitivity and shorter 
analysis time using a chemometric protocol (statistical experimental design and Derringer's 
desirability function) was developed for simultaneous analysis of amlodipine and 
atorvastatin in pharmaceutical formulations [53]. Three HPLC methods have been published 
for analysis of atorvastatin and acetylsalicylic acid in combination with clopidogrel [54] and 
ramipril [55]. 
 
Figure 2. Total ion current chromatogram of atorvastatin pharmaceutical dosage form (A) and MS 
spectra of its process related impurity diamino-atorvastatin (B) 
(a)
(b)
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HPLC method was used for investigation of polypills for the treatment of cardiovascular 
diseases [56]. Seven drugs, i.e. lisinopril, aspirin, atenolol, hydrochlorothiazide and 
simvastatin/pravastatin/atorvastatin in the presence of their major interaction and 
degradation products were separated on a C8 column. In order to obtain mass spectra of the 
interaction and degradation products, ESI-MicroTOFQ mass spectrometer was employed. 
Atenolol, lisinopril, simvastatin and atorvastatin mass spectra were acquired in positive ESI 
mode, while hydrochlorotiazide and aspirin were ionized better in negative mode. 
Pravastatin gave good molecular ions in both modes. All the interaction and degradation 
products gave satisfactory mass spectra in positive ESI modes, except for two pravastatin 
related products which showed better molecular ions in negative mode. Results suggested 
that use of pravastatin in relate to other statins resulted in more interaction and degradation 
products, as well did the combination with atenolol by comparison with hydrochlorotiazide. 
This is a very nice approach that can be utilized for drug-drug interactions and stability 
studies of the polypill. Drawbacks of the proposed method are long analysis time of 90 min, 
replacement of the phosphate buffer with water for MS analysis and three different gradient 
methods for each of the statins.  
2.6. Rosuvastatin 
Far to our knowledge first HPLC method for the determination of rosuvastatin in bulk drug 
and in its dosage form was published by Mehta et al [57]. A forced degradation study was 
done at various pH values, under hydrolytic, oxidative, photolytic and thermal stress 
conditions. Developed method was able to resolve the degradation products formed during 
the stress study.  
Not so commonly used in quality control analysis of pharmaceuticals, HPTLC method was 
proposed [58] for determination of rosuvastatin in its bulk drug and pharmaceutical 
preparations. Analysis was performed in a Camag twin-trough chamber on silica gel 
60F(254) HPTLC plates. Aceclofenac was used as internal standard. Optimized mobile phase 
consisted of toluene-methanol-ethyl acetate-formic acid. Quantitation was performed 
densitometrically at 265 nm.  
A paper employing both HPTLC and HPLC for determination of rosuvastatin and ezetimibe 
in combined tablet dosage forms was published [59]. HPLC analysis was performed on a 
Chromolith C18 column (100 mm x 4.6 mm) with PDA detector set at 245 nm. HPTLC 
separation was carried out on an aluminum-backed sheet of silica gel 60F (254) layers using 
n-butyl acetate-chloroform-glacial acetic acid as the mobile phase. Quantification of analites 
was performed with UV densitometry at 245 nm. A stability indicating method for 
simultaneous estimation of rosuvastatin and ezetimibe in their combination drug product 
was introduced [60]. Under oxidation, thermal and photodegradation conditions, both 
drugs were relatively stable. For rosuvastatin a high degree of degradation was observed in 
acidic hydrolytic conditions (0.1 M HCl at 80 °C for 1h), while ezetimibe was stable. On the 
contrary, ezetimibe was completely degradated with 0.1 M NaOH at 80 °C in 30 min, while 
rosuvastatin remained stable.  
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Simultaneous determination and quantification of atenolol, rosuvastatin, spironolactone, 
glibenclamide and naproxen sodium in bulk drugs, pharmaceutical formulations and in 
spiked human plasma was performed by HPLC [61].  
2.7. Pitavastatin  
Pitavastatin is the newest statin on the market available in Japan since 2003, and approved 
for use in US in 2009. Currently pitavastatin is under evaluation in Europe (in UK it was 
approved in 2010). Hence, not many methods have been reported for determination of 
pitavastatin in bulk drug and pharmaceutical formulations.  
Two HPTLC methods were reported for the determination of pitavastatin in commercial 
pharmaceutical dosage forms [62, 63]. Validation was performed and both methods were 
shown to be selective, sensitive and accurate.  
A HPLC method was proposed for determination of pitavastatin in pharmaceutical dosage 
forms by Kumar et al [64]. Separation was achieved on a Phenomenex C18 column (250 mm 
x 4.6 mm, 5 μm) in isocratic mode. Different mobile phases were tested and based on the 
best separation, analysis time, cost-effectives, sensitivity and suitability for the stability 
studies, a mobile phase consisted of 0.5% acetic acid:acetonitrile (35:65, v/v) was chosen. 
Four different drugs were tried out as the internal standard, and based on peak shape, 
resolution and elution time, paracetamol was chosen.  
Several stability indicating methods have been published [65-68]. Panchal and co-workers 
proposed two different methods, using liquid chromatography and ultraviolet 
spectrophotometry for determination of pitavastatin in tablet dosage forms [66]. Additionally 
forced degradation study was conducted under acidic, basic, oxidative, thermal and photolytic 
conditions. No change in the area of pitavastatin peak and no additional peaks were detected 
under photodegradation conditions. Both acidic and basic hydrolysis and thermal conditions 
generated additional peaks. After oxidative degradation a significant decrease of pitavastatin 
peak and additional peaks were observed. Linearity range of the LC method was 0.1-2.5 
μg/mL, while for the UV method it ranged from 2-20 μg/mL. The limit of detection (LOD) of 
the LC method was 0.0055 μg/mL, whereas for the UV method it was much higher, 0.4062 
μg/mL. Statistical comparison between two methods by applying the paired t-test was 
performed and no statistically significant difference was observed.  
UPLC stability indicating method was developed for degradation study of pitavastatin [67]. 
Separation of pitavastatin and its degradation products and impurities was performed in 
less then 5 min. More detailed photodegradation study of pitavastatin was conducted by 
Grobelny et al. [68]. Pitavastatin solution was exposed to UV-A radiation. HPLC analysis 
was performed to monitor the changes of pitavastatin. Identification of four photoproducts 
was conducted by MS analysis.  
A single method is reported for simultaneous determination of pitavastatin and ezetimibe 
[69]. After optimization and validation, the proposed method was successfully applied for 
determination of pitavastatin and ezetimibe in a prepared binary mixture. However, no real 
sample was tested.  
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Analyt Application Separation 
technique and 
detector 
Stationary phase Mobile phase Ref. 
LOV  stability 
indicating study 
HPLC 
PDA 237 nm 
Symmetry C18 (150 x 
3.9 mm, 5 μm) 
Gradient elution 
A: ACN 
B: 0.1% TFA  
15 
SIM, EZE combined 
dosage form 
HPLC  
UV 240 nm 
Chromolith 
Performance 
monolitich column 
RP-18e  (250 x 4.6 mm)
ACN:50 mM ammonium 
acetate (65:35) 
25 
SIM impurity 
profiling 
HPLC  
DAD 240 nm,  
ESI-ion trap 
Symmetry Shield RP 
18 (250 x 4.6 mm, 5 
μm) 
ACN:water (85:15)  
 
26 
SIM combined 
dosage form 
UPLC 
Q-TOF MS 
Acquity BEH C18 (100 
x 2.1 mm, 1.7 μm) 
gradient elution 
ACN:ammonium acetate pH 
6 
28 
PRA impurity 
profiling 
HPLC  
APCI-CAD MS
Betasil C18 (250 x 4.6 
mm)  
gradient elution 
A: 30%methanol+10 mM 
ammonium acetate 
B: 100% methanol + 10 mM 
ammonium acetate 
32 
PRA stability 
indicating study 
HPLC 
UV 238 nm 
Alltima C18 (150 x 4.6 
mm, 5 μm) 
methanol:0.02 M phosphate 
buffer pH 7 
 
33 
ATO, 
AML 
stability 
indicating study 
HPLC 
UV 237 nm 
Perfectsil Target ODS-
3 (250 x 4.6 mm, 5 μm)
ACN:0.025 M sodium 
dihydrogen phosphate pH 
4.5 (55:45) 
39 
ATO, 
ASA 
stability 
indicating study 
UPLC  
UV 247 nm 
BEH C18 (50 x 2.1 mm, 
1.7 μm) 
ACN:0.1 M phosphate buffer  40 
ATO, 
FEN 
stability 
indicating study 
UPLC 
UV 247 nm 
BEH C18 (50 x 2.1 mm, 
1.7 μm) 
ACN:0.01 M ammonium 
acetate pH 4.7 
43 
ATO related 
compounds 
HPLC 
UV 248 nm 
Zorbax XDB C18 
Rapid Resolution HT 
(50 x 4.6 mm, 1.8 μm) 
gradient elution  
A: Tetrahydrofuran:ACN 
(90:10) 
B: 0.025M phosphate buffer 
pH 3.5  
45 
ATO, 
RAM 
combined 
dosage form 
HPLC 
HPTLC 
Phenomenex Luna 
C18 (250 x 4.6 mm, 5 
μm) 
Silica gel 60F254 
0.1% phosphoric acid:ACN 
(38:62)  
methanol-benzene-glacial 
acid (19.6:80.0:0.4) 
 
47 
ATO, 
FEN 
combined 
dosage form 
TLC 
UV 258 nm 
Aluminum foil silica 
gel 60 F-254 
toluene-methanol-
triethylamine (7:3:0.2) 
 
48 
ATO, 
SIM, 
PRA 
pharmaceutical  
dosage form  
 
HPLC  
UV 225 nm 
ESI-QTOF MS  
Supelco C8 (250 x 4.6 
mm, 5 μm) 
gradient elution 
A: ACN 
B: phosphate buffer pH 2.3 
56 
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Analyt Application Separation 
technique and 
detector 
Stationary phase Mobile phase Ref. 
ROS, 
EZE 
combined  
dosage form 
HPLC 
HPTLC  
UV 245 nm 
Chromolith C 18 (100 
x 6 mm) 
Aluminium-backed 
silica gel 60F(254) 
0.1% orthophosphoric acid 
pH 3.5:ACN (63:37)  
59 
ROS, 
EZE 
stability 
indicating study 
HPLC  
UV 242 nm 
Hypersil C18 (150 x 4.6 
mm, 5 μm) 
0.05 M phosphate buffer pH 
2.5:methanol (45:55)  
60 
PIT pharmaceutical  
dosage form 
HPTLC  
UV 245 nm 
Aluminum backed 
Silica gel 60F(254) 
ethyl acetate-methanol-
ammonia+1drop formic acid 
(7:2:0.8) 
62 
PIT photostability 
study 
HPLC 
MS 
LiChrospher RP-18 
(250 x 4.6 mm, 5 μm)   
gradient elution 
A:ACN 
B:10 mM phosphate buffer  
66 
ROS, 
ATO, 
SIM, 
LOV, 
PRA 
pharmaceutical  
dosage form 
HPLC 
GC  
UV 246 nm 
Symmetry C18 (250 x 
4.6 mm, 5 μm) 
HP-1 (30 m x 0.25 mm 
x 0.25 μm) 
ACN:water (70:30) pH 2.5 
1.2 mL/min 
2.9 mL/min (GC) 
123 
PRA, 
FLU, 
ATO, 
ROS 
stability 
indicating study 
HPLC RP C18 methanol-water (60:40)-
PRA,ROS  
Methanol-water (70:30)-
FLU,ATO   
124 
LOV-lovastatin, SIM-simvastatin, PRA-pravastatin, FLU-fluvastatin, ATO-atorvastatin, ROS-rosuvastatin, PIT-
pitavastatin, EZE-ezetimibe, AML-amlodipine, ASA-acetylsalicylic acid, FEN-fenofibrate, RAM-ramiprile, ACN-
acetonitrile 
Table 1. Chromatographic methods for analysis of statin drugs in pharmaceuticals 
3. Bioanalytical methods 
There have been three reviews on analytical methods for the determination of HMG-CoA 
reductase inhibitors in biological samples. The first one, published by Ertürk and co-
workers in 2003 [70], reviews bio-analytical methods for lovastatin, simvastatin, pravastatin, 
fluvastatin and atorvastatin. The second one, published in 2007, is focused only on 
chromatography-mass spectrometry methods for the quantification of statins in biological 
samples [10]. In 2008 Nováková and co-workers [17] have published a review on HPLC 
methods for the determination of simvastatin and atorvastatin in various fields of 
application, including bioanalytical assays. Since these reviews have been published, a 
number of bioanalytical methods have been developed for all HMG-CoA reductase 
inhibitors. Most of the methods published since 2007 were applied for investigation of 
HMG-CoA reductase inhibitors in human plasma or serum. Far to our knowledge since 2007 
only two LC/MS/MS methods for determination of statins in human urine have been 
developed. The sample preparation procedures and analytical assays for quantification of 
statins in biological samples are listed in Tables 2 and 3. 
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3.1. Sample preparation 
Sample preparation is a quite tedious but still unavoidable procedure in bioanalitical 
methods. The objective of this delicate and challenging step is to transfer analyte of interest 
into a form that is purified, concentrated and compatible with the analytical system. The 
extraction and enrichment of analytes from the sample matrix are often realized by 
procedures such as, protein precipitation, liquid-liquid extraction (LLE) and solid-phase 
extraction (SPE). These conventional sample preparation procedures are still dominating in 
the preparation of biological samples for determination of statin drugs as well as their 
metabolites. 
In most of the methods protein precipitation reagent is used as a dilution solvent for internal 
standard in order to reduce the number of reagent additions [71-74]. Still, Apostolou and co-
workers [75] suggested addition of protein precipitation reagent after the internal standard 
in order to ensure a more satisfying binding of internal standard molecules with plasma 
proteins, simulating the binding of proteins with analytes in real human plasma. A number 
of different protein precipitation reagents were tested [76]. Despite the good recoveries 
obtained with phosphoric acid, the authors recommended to avoid acidic precipitants due 
to degradation of fluvastatin in acidic conditions. The highest recoveries were obtained with 
organic solvents. Although no significant differences were observed between methanol and 
acetonitrile, the second one was used as it offered a more compact precipitate minimizing 
the risk of SPE cartridge obstruction.  
The simplest way to concentrate the analyte is certainly LLE. Hence, Hamidi and co-workers 
[73] tested a wide spectrum of organic solvents from various physicochemical categories 
with different volume fractions as well as combinations for extraction of lovastatin from 
human plasma. The best extraction efficacy was obtained using diethyl ether as extraction 
solvent. The same solvent was used for extraction of pitavastatin from human plasma [77]. 
An addition of hidrocloric acid to the plasma samples afore the extraction procedure was 
shown to be necessary in order to obtain the non-ionized form of analyte which 
considerably improved extraction efficacy. Assays employing LLE with ethyl acetate [78] 
and ethyl ether [79] as extraction solvents for determination of rosuvastatin in plasma 
samples were already published with extraction recoveries of 74 and 69%, respectively. 
However, in the preliminary study by Lan and co-workers [80], it was found that the 
extraction recovery of rosuvastatin from plasma in most common organic solvents, such as 
above mentioned ethyl acetate and ethyl ether, was less than 20%, resulting in an 
insufficient, imprecise and inaccurate extraction procedure. The authors presumed that low 
extraction efficacy of rosuvastatin was due to its extremely low water solubility. However, a 
carboxyl group in its structure forms a salt with calcium ion which indicates that 
rosuvastatin was apt to ionization. The application of ion paring with tetrabutyl ammonium 
hydroxide was suggested for improvement of rosuvastatin solubility and subsequently 
extraction efficacy. Finally, using ion paring LLE, extraction efficacy of rosuvastatin in ethyl 
acetate was improved from around 10% to more than 50%. A somewhat unusual LLE 
method for determination of timolol maleate, rosuvastatin and diclofenac in human plasma 
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and aqueous humor from the bovine eyes was proposed [81]. The mobile phase, consisted of 
acetonitrile and 0.2% triethylamine, was used as extraction solvent. The quite high 
extraction efficacy of all investigated compounds was obtained using this uncommon 
extraction solvent.  
Although LLE is generally considered to be providing cleaner extracts and lower matrix 
effect than the SPE, lower recovery due to the transfer of a fraction of the organic extract 
after the extraction may be the main disadvantage of the LLE technique. Moreover, when 
low concentrations have to be detected it is necessary to use a large solvent volumes and 
sample preparation becomes time consuming and labor invasive. In order to reduce organic 
solvent consumption, sample volume and sample preparation time, Apostolou and co-
workers [75] have presented a fully automated high-throughput two-step LLE-LC/MS/MS 
method for the quantification of simvastatin and its acid form using a robotic liquid 
handling workstation with 96-deepwell plates. Another fully automated high-throughput 
salting-out (SA) assisted LLE-LC/MS/MS method was introduced by Zhang and co-workers 
[82]. Due to the compatibility between SALLE and LC/MS/MS, the extracts of simvastatin 
and its acid from human plasma were injected directly into LC system immediately after 
sample extraction. In this way extract solvent evaporation was eliminated and consequently 
sample preparation procedure was simplified. Also, the exposure of the extracts to the room 
temperature was minimized and hence minimal interconversion between simvastatin and 
its acid was achieved.   
Among the SPE methods, the reverse phase cartridges have been extensively used for 
extraction of statins from biological samples. Gonzalez and co-workers [76] have presented a 
nice work regarding the traditional one-variable-at a time optimization for SPE extraction of 
fluvastatin together with other drugs from human plasma. The optimization of conditioning 
and washing solution composition, pH for conditioning and washing step and elution 
solvent selection were described in details. The SPE procedure has also been used as sample 
preparation step for quantification of atorvastatin and simvastatin as well as their 
metabolites in serum from patients with end stage renal disease [83]. In order to obtain the 
satisfactory and repeatable extraction efficacy and to remove matrix effects, several different 
reversed-phase SPE sorbents have been tested. The best results were obtained using 
ZORBAX SPE C-18 (Agilent Technologies) and Discovery DSC-18 SPE (Supelco) cartridges. 
As ZORBAX SPE C-18 columns were withdrawn from commercial market circulation 
during optimization of method, further investigations were performed using Discovery 
DSC-18 SPE cartridges. For the purpose of minimization of the interconversion between 
lacton and open-ring hydroxy acid forms of simvastatin and atorvastatin, SPE sorbents were 
conditioned and analytes were eluated with solvents containing 0.1 M acetate ammonium 
buffer pH 4.5. In the work of Di and co-workers [84) SPE sample preparation procedure was 
used for determination of pitavastatin with rosuvastatin as internal standard in human 
plasma. The influence of pH on extraction efficacy of statin drugs was investigated in detail. 
The authors have pointed out importance of 0.5 M potassium dihydrogenphosphate buffer 
(pH 4.0) as conditioning reagent for cartridges. At pH lower than 4 both molecules were 
protonated, leading to a decrease in its partitioning in reversed-phase SPE and recovery. At 
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pH higher than 4, the carboxylic group in both pitavastatin and rosuvastatin undergo 
ionization, which also resulted in a decrease in the recovery for the same reason. 
Furthermore, it was found that pitavastatin degradation was much faster at lower than at 
high pHs. Also, it was found that pitavastatin was sensitive to sunlight. It was 
recommended to minimize the exposure of samples to sunlight as well as to dissolve the 
dried extract rather in methanol and water than in mobile phase containing formic acid.  
To reduce the time of sample preparation, Mertens and co-workers [85] have used an 
automated SPE on disposable extraction cartridges to isolate pravastatin and its metabolites 
together with fenofibric acid, another lipid-regulating agent, from the human plasma and to 
prepare cleaner samples before injection and analysis in the LC/DAD/MS/MS system. 
Different kinds of disposable extraction cartridges containing bonded silicas of different 
polarities (ethyl, endcapped ethyl, octyl, endcapped octyl, octadecyl, endcapped octadecyl 
and cyanopropyl) were tested. The best recoveries for all investigated compounds were 
reported when disposable extraction cartridges filled with octyl functionalized silica sorbent 
were used. 
Unfortunately, conventional SPE and LLE approaches are multi-step, time-consuming and 
the sample required for analyses as well as the consumption of organic solvent are quite 
high, particularly in case of LLE. A solvent-minimized sample preparation approach has 
been popular in last decades, therefore Farahani and co-workers [71] have published liquid-
liquid-liquid microextraction procedure (LLLME), a miniaturized format of LLE, for 
determination of atorvastatin in human plasma. A number of factors affecting the 
microextraction efficiency were studied in detailed and the optimized conditions were 
established. They have obtained quite high extraction efficacy of atorvastatin from human 
plasma using proposed sample preparation procedure. Vlčková and co-workers [86] have 
developed fast and simple extraction procedure using microextraction by packed sorbent 
(MEPS) for sample purification and concentration of atorvastatin and its metabolites from 
human serum. Briefly, MEPS is a miniaturization of conventional SPE, but it differs from 
commercial SPE by fact that packing is inserted directly into the syringe, not into a separate 
column. In addition, they have compared a previously described [83] SPE procedure for 
extraction of atorvastatin and its metabolites from human serum with newly developed 
MEPS approach. The results of samples treated by SPE and MEPS were compared by means 
of Student t-test. The difference between obtained concentrations was statistically not 
significant. Hence, MEPS procedure was found to be simpler and faster sample preparation 
technique using smaller volume of sample, which is regardful to the patients and smaller 
volume of solvents, which is environmentally friendly. 
3.2. Liquid chromatography 
3.2.1. High performance liquid chromatography 
The high performance liquid chromatography has become the method of choice for 
bioanalytical methods. Generally, in the HPLC methods reversed-phase C18 
chromatographic columns were used for analysis of statin drugs in biological fluids. The 
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recently developed columns based on BEH particles technology were employed in several 
methods [83, 86, 87]. Only in one assay reversed-phase C8 chromatographic column was 
used [88]. Unusually, reversed-phase narrow bore phenyl column was employed for 
investigation of atorvastatin, rosuvastatin and their metabolites [74, 89]. The length and 
diameter of columns differed fairly from 50 to 250 mm and from 2.0 to 4.6 mm, respectively. 
Although in most of the cases columns with particle size 5 μm were used, several authors 
preferred columns with smaller particles in order to obtain better peak shapes, resolution 
and thus shorter analysis time [72, 82, 83, 86, 87]. Analytical run times have been very 
variable, the shortest 2 min, the longest about 20 min.  
The selection of mobile phase was quite a challenging task in all investigations. In most of 
the methods acetonitrile or methanol were present in the mobile phase as organic solvent. 
The percentage of organic solvents was optimized such that the retention times of analytes 
were kept as short as possible. In most assays percentage of organic solvent was quite high, 
usually more than 70%. The majority of publications emphasize the pH as the most critical 
variable for separation of the statin drugs [76, 82, 84]. In order to minimize the 
interconversion, it is critical to maintain pH of mobile phase between 4 and 5.  
The influence of mobile phase pH on retention of atorvastatin and rosuvastatin has been 
investigated [90]. Since both of the analytes are acidic compounds, their retention on the 
reversed-phase column was expected to be pH dependant. When pH of the mobile phase 
was decreased from 4.0 to 3.0, the retention times of the analytes decreased unexpectedly 
and with further decreases in the pH to 2.0 the retention times increased once again. This 
behavior was explained by a change in binding of the analytes to the stationary phase and 
also changes in the solubility of the analytes in the mobile phase. The pH 3.0 was chosen as 
optimum pH because of the reasonable retention times while the resolution between peaks, 
as well as peak shapes, were satisfactory.  
The pH of mobile phase was also a critical variable for the separation of the fluvastatin from 
valsartan and its metabolite during the optimization of LC/PDA/FLD method [76]. The pH 
of the mobile phase was limited by the native fluorescence of valsartan and its metabolite, 
which disappears in the basic form (pKa = 3.7). On the other hand, spectrophotometric 
studies showed that fluvastatin degradation was accelerated in acidic conditions. Mobile 
phases with different formic acid/formate proportions were tested in order to establish the 
range where fluvastatin was stable and valsartan and its metabolites kept their fluorescence. 
0.01% formic acid/10 mM ammonium formate (pH 4.1) was finally chosen as appropriate 
buffer. Uncommon pH was used for quantification of lovastatin in human plasma [73]. 
Mobile phase consisted of acetonitrile and 0.05 M phosphate buffer with pH 7, adjusted with 
phosphoric acid.  
The flow rate of the mobile phase was in range from 0.2 up to 1.5 mL/min. In all of the 
assays the flow rate did not change during the chromatographic analysis except in the 
reference [76] where the flow rate was gradually changed after three minutes.  
The chromatographic separation of most of the methods was performed at room 
temperature. In order to shorten analysis time, in the several cases the column temperature  
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Extracted analytes Matrix Sample 
preparation 
procedure
Stationary 
phase 
PP reagent / 
LLE reagent /  
SPE eluent
Recovery  
(%) 
Ref. 
ATO plasma PP, LLLME - methanol , HCl, 
trichloroacetic acid 
/1-octanol
91 71 
SIM, MET 
IS=propranolol 
hydrochloride 
plasma PP - methanol:water 
(1:1) 
83-91 72 
ROS + metabolites 
IS=deuterium labeled
plasma PP - 0.1% acetic acid  in 
methanol
88–106 74 
FLU, VAL + metabolite, 
CLT 
IS=candesartan cilexetil
plasma PP, SPE Phenomenex 
Strata-X 
polymeric C18
ACN/methanol 78–91 76 
ROS 
IS=hydrochlorothiazide
plasma LLE - ethyl ether 69–72 79 
ROS 
IS=estrone 
plasma ion pair LLE - ethyl acetate 47–63 80 
ROS, TIM, DIC 
IS=naproxen  
plasma, 
bovine 
aqueous 
humor
PP, LLE - methanol/mobile 
phase 
95–99 81 
SIM, SIM-acid 
IS=deuterium labeled 
plasma SALLE - ACN, 5 M 
ammonium 
formate buffer (pH 
4.5)
71–79 82 
SIM, ATO + metabolites
IS= deuterium labeled   
serum SPE Supelco 
Discovery DSC-
18 
ACN:0.1 M 
ammonium acetate 
buffer pH 4.5 (95:5)
65-100 83 
PIT 
IS=ROS 
plasma, 
urine 
SPE Supelco 
SupercleanTM 
LC-18 SPE 
Tubed
methanol plasma 
84–88 
urine 86–
96 
84 
PRA + metabolites, FFA
IS=triamcinolone 
plasma at-SPE Disposable 
extraction 
cartridges C8 
silica sorbent
methanol 50–77 85 
ATO + metabolites
IS=deuterium labeled 
serum MEPS C8 ACN:0.1 M 
ammonium acetate 
pH 4.5 (95:5)
89–116 86 
PIT, PIT-lactone 
IS=racemic i-prolact 
plasma, 
urine 
LLE - methyl-terc-butyl 
ether 
plasma 
70–75 
urine 74–
83 
88 
PRA, ASA 
IS=furosemide 
plasma LLE - tertiary butyl 
methyl ether
51–66 94 
SIM-simvastatin, PRA-pravastatin, FLU-fluvastatin, ATO-atorvastatin, ROS-rosuvastatin, PIT-pitavastatin, FFA-
fenofibric acid, TIM-timolol maleate, MET-metoprolol, DIC-diclofenac, VAL-valsartan, ASA-acetylsalycilic acid, CLT-
chlorthalidone, ACN-acetonitrile, IS-internal standard 
Table 2. Sample preparation procedures utilized for the determination of statins in biological samples 
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was maintained above 30 °C [76, 77, 81, 83, 86, 87].  The effect of column oven temperatures 
on the analysis of atorvastatin and rosuvastatin in the range 25 to 35 °C was investigated 
and best results were observed at 25 °C in terms of retention factor and resolution [90]. 
Increasing temperature above 25 °C resulted in the rapid elution of rosuvastatin close to the 
solvent front.  
LC/DAD methods are rarely sensitive enough for quantification of statins as well as their 
metabolites in human plasma samples due to the poor UV-absorption properties of statin 
molecules. Furthermore, the levels of statins and their metabolites in biological fluids are 
very low due to low amount of drug reaching the systemic circulation. Their typical plasma 
concentrations are in ng/mL levels. However, several sensitive LC/DAD methods for 
determination of pravastatin [31], atorvastatin [71], lovastatin [73], rosuvastatin [81], and 
atorvastatin with rosuvastatin [90] have been developed with limit of quantification (LOQ) 
in range of 1 - 10 ng/mL. Less sensitive LC/DAD method for quantification of lovastatin in 
human plasma was developed [91]. The LOQ value for lovastatin was relatively high, 400 
ng/mL. Another even less sensitive LC/DAD method for quantification of several HMG-
CoA reductase inhibitors in human plasma was developed by Sultana and co-workers [92]. 
The LOQ values were between 376 and 1006 ng/mL. In fact, both of these methods were not 
used on real plasma samples.   
Fluorescence detection has not been widely employed in the determination of HMG-CoA 
reductase inhibitors, as most of statins do not possess a natural native fluorescence. Still, 
Gonzalez and co-workers [76] have developed a SPE-HPLC/PDA/FLD method for 
determination of fluvastatin and valsartan in human plasma. Comparing results obtained 
with spectrophotometic and fluorimetric detector superior selectivity and sensitivity by 
fluorescence detection of fluvastatin could be perceived.  
3.2.2. Ultra performance liquid chromatography 
Recently UPLC is becoming a leading chromatographic technique in modern bio-analytical 
methods. Nováková and co-workers [83] have investigated its potential in combination with 
MS/MS detection for the fast, sensitive, reliable and selective detection of atorvastatin and 
simvastatin together with their main metabolites and interconversion products in human 
serum. Iriarte and co-workers [87] have investigated UPLC technique as a faster alternative 
to HPLC for simultaneous analysis of fluvastatin and other drugs usually prescribed in 
cardiovascular therapy. Acquity UPLC Columns Calculator software was used for transfer 
of previously developed HPLC method [76].  
The UPLC technology has significantly improved the method optimization process since shorter 
analysis and re-equilibration times allowed a greater number of experimental testing conditions 
than with a conventional HPLC. The sample volume required was much lower than in HPLC 
method. Furthermore, shorter analysis time together with slower flow rates reduced the organic 
solvent consumption. The sharper and higher chromatographic peaks, thereby improved peak 
capacity, was obtained using UPLC technology. Still, the sensitivity of UPLC method was found 
to be analyte dependent as the improvement was not achieved for all analytes.     
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3.2.3. Liquid chromatography coupled to tandem mass spectrometry 
In pharmacokinetic investigations of statins LC/MS/MS technique is unequivocally the 
method of choice. Recently, several procedures were described in the literature taking the 
advantages of the benefits of mass spectrometry. Both ESI and APCI sources as well as triple 
quadrupole analyzator were applied in most LC/MS/MS sample analysis.  
As it was mentioned above the selection of appropriate mobile phase composition for 
determination of statins in biological fluids is quite challenging task which is even more 
complicated when detection and quantification of statins is performed using MS. Only few 
additives could enable good stability at pH range 4 to 5 as well as volatility and sensitive 
mass spectrometric response. Therefore, Di and co-workers [84] have pointed out the 
importance of the formic acid in lowering the pH of mobile phase. In this way pitavastatin 
was obtained in non-ionized form and a symmetrical peak shape was observed. The 
concentration of formic acid was optimized not only to maintain a symmetrical peak shape 
in the chromatographic system but also to render good ionization and fragmentation of 
pitavastatin in the MS/MS detector. An addition of 0.025% formic acid to the aqueous phase 
was found to be an important factor for acquiring the high sensitivity of another LC/MS/MS 
method for determination of pitavastatin in human plasma [77].  
Nováková and co-workers [83] have presented a nice example of optimization of the buffer 
pH and concentration in order to get the best signal to noise ratio of MS detector. 
Ammonium formate and ammonium acetate at pH 4.0 and 4.5 were tested at the 
concentration range 0.01 to 10 mM. The best response of atorvastatin and simvastatin was 
observed at 0.5 mM buffers. The concentrations higher than 5 mM significantly decreased 
the response of mass spectrometer. On the other hand, the concentrations lower than 0.5 
mM were not sufficient to keep buffering capacity and thus had negative influence to the 
response of mass spectrometer. Ammonium acetate was preferred before ammonium 
formate because of better peak shapes. Finally, the optimized mobile phase composition was 
70% of acetonitrile and 30% of ammonium acetate buffer 0.5 mM (pH 4.0). In most of 
bioanalytical methods isocratic elution has been utilized, still when more analytes with 
different polarities were separated, gradient elution had to be applied. 
Tandem mass spectrometry detection for identification and quantification of simvastatin 
and atorvastatin together with their metabolites and lacton/hidroxy acid interconversion 
forms was employed [83, 86]. All analytes were monitored using electrospray positive 
ionization (ESI+) mode and for all analytes protonated molecule [M+H]+ was the most 
intensive ion in mass spectra. Quantification of all analytes was performed using selected 
reaction monitoring (SRM) and two specific transitions were optimized for each molecule in 
order to increase selectivity and sensitivity of the method. In the paper published afterwards 
simvastatin in its lactone form was determined in ESI+ mode, while its hydroxy acid form 
was determined in ESI- mode due to poor sensitivity of hydroxy acid form in positive ion 
mode [82].  
LC/MS/MS method developed by Apostolou and co-workers [75] consisted also of two 
periods combining both negative and positive ionization modes. The mass spectrometer 
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operated in the negative detection mode for 1.21 min until simvastatin and lovastatin 
hydroxy acid forms were eluted from chromatographic column. Afterwards a period of 0.69 
min followed in the positive mode during witch simvastatin and lovastatin lacton forms 
were eluted. Comparing LOQ values for simvastatin acid obtained by these three methods it 
can be seen that lower LOQ values and thus better sensitivity were obtained in the last two 
methods. Unfortunately, simvastatin forms various adducts influenced by mobile-phase and 
matrix composition and such adducts sometimes give higher intensity than protonated 
molecule [M+H]+, which is an ideal precursor ion for SRM transition and quantification 
studies. However, Senthamil Selvan and co-workers [72] have observed very high signal of 
[M+Na]+ in the spectra of simvastatin next to the [M+H]+.  Consequently, it was used as 
precursor ion for quantitation of simvastatin. Also, Zhang and co-workers [82] have used 
the methylammonium aduct [M+CH3NH4]+ as a parent ion for simvastatin because the 
adduct ion showed the best signal to noise ratio. 
Rosuvastatin has a pyrimidine ring and a carboxylic group in its structure, hence it could be 
detected either in positive or negative ionization mode. However, the quantification of 
rosuvastatin in positive ionization mode is more common and was used for determination 
of rosuvastatin [80] and rosuvastatin together with its metabolites [74], respectively. In the 
both assays the major ion was protonated molecule [M+H]+ in full-scan mode and principal 
product ion was at m/z 482. Macwan and co-workers [74] have also reported two minor 
fragments at m/z 300 and m/z 272.  
During the method development, Gao and co-workers [79] also attempted to optimize ESI 
conditions under positive ionization mode. However, the observed signal intensity was not 
sensitive enough for determination of expected rosuvastatin’s concentrations, especially for 
low dosage administration. Low sensitivity of positive ionization mode could be explained 
by a number of fragment ions produced in the product ion spectrum of [M+H]+. In order to 
improve the sensitivity of the method, the negative ESI detection was taken into 
consideration. Under negative ESI mode, rosuvastatin produced abundant deprotonated 
molecule [M-H]- at m/z 480. In the product ion mass spectrum of [M-H]-, fewer fragment 
ions were formed compared with that of [M +H]+. Also, it was pointed out that negative ESI 
mode produced lower chemical background noise than positive. Comparing LOQ values 
obtained by these three methods, it can be observed that almost five times lower LOQ value 
for rosuvastatin was obtained using negative ESI detection.  
Pitavastatin has similar structure to rosuvastatin. It contains alkaline nitrogen ion on the 
quinoline ring and a carboxylic group, therefore positive and negative ionization mode 
could be also employed. Both of ionization modes for determination of pitavastatin in 
human plasma and urine by LC/MS/MS method were applied [84]. The results showed that 
the response intensity of pitavastatin in negative mode was lower and furthermore the 
response was quite unstable. Pitavastatin was scanned under Q1 MS full-scan mode to 
determine the parent ion and under Q1/Q3 product ion scan mode to locate the most 
abundant production. The protonated molecular ion, [M+H]+, was the predominant ion in 
the Q1 spectrum and was used as the parent ion to obtain the product ion spectra. The most 
sensitive mass transition was from m/z 422.0 to 290.1, which was similar to the MS/MS 
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spectrum of pitavastatin reported in reference [88] and  [93], while in the previously 
reported LC/MS/MS method the highest collision energy gave the most abundant product 
ion at m/z 318.0 [77]. 
Recently, two LC/MS/MS methods have been developed for determination of pravastatin in 
human plasma [85, 94]. Both methods utilized ESI but in different modes. In the method 
developed by Martens and co-workers [85] the mass spectrometer was operated in the 
positive mode. The MS/MS detection was set up in MRM mode. The full scan mass spectra 
of pravastatin and its metabolites were scanned. The collision energy in Q2 produced 
different significant fragment ions. The MS/MS ion transitions selected for quantification 
purpose were m/z 442.2 to 269.1, 442.2 to 269.1 and m/z 424.3 to 183.0 for pravastatin, 3-OH 
metabolite and its lacton form. On the contrary, Polagani and co-workers [94] have found 
high sensitivity and stability using negative ionization mode. Deprotonated form of 
pravastatin, [M-H]- ion was the parent ion in the Q1 spectrum and was used as the precursor 
ion to obtain Q3 product ion spectra. The most sensitive mass transition was monitored 
from m/z 423.3 to 100.8.  
Internal standards have been used in most of the assays leading to more corrected results. In 
some cases one of the statins has been used as internal standard [73, 75, 77, 84], while other 
works utilized internal standards of various structure, including hydrochlorothiazide [79], 
estrone [80], naproxen [90], gemfibrozil [91], pioglitazone [95] etc. The best internal 
standards for precise and accurate quantification in MS or tandem MS are stable-isotope-
labeled standards. Only a few works employed deuterium labeled standards [74, 82, 83, 86]. 
In the case of atorvastatin, [d5] labeling usually occurs on the phenyl ring, which does not 
contain fluorine. [d3] labeling of simvastatin occurs on the side chain, while [d6] labeling of 
rosuvastatin occurs on isopropyl group attached to pyrimidin ring. In most of investigations 
only one compound was used as internal standard.  
However, Mertens and co-workers [85] have used two different internal standards for 
quantification of fenofibric acid, pravastatin and its metabolites in human plasma by 
automated SPE-LC/DAD/MS/MS technique. To avoid the need for plasma dilution and two 
time-consuming analytical runs, the use of two internal standards was necessary as the 
concentration of fenofibric acid was too high and MS signal appeared saturated. Hence, the 
sulindac was selected for the quantification of fenofibric acid by UV-detector, while the 
triamcinolone was used for MS/MS quantification of pravastatin and its metabolites. As it 
was mentioned above, in the method developed by Zhang and co-workers [82], the 
LC/MS/MS data acquisition for simvastatin was conducted in positive ionization mode, 
whereas the data acquisition for simvastatin acid was conducted in negative ionization 
mode. Therefore, it was inevitable to use two internal standards deuterium labeled 
simvastatin and deuterium labeled simvastatin acid, respectively. 
3.3. Gas chromatography 
Several GC/MS methods for determination of statins in biological samples have been 
reported [10]. Unfortunately, these methods are limited and not recommended for routine 
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applications as they include analyte derivatization step prior to anaysis in order to obtain 
volatile derivatives of the drug molecule and therefore a complicate sample preparation 
procedures.  
Simultaneous determination of lovastatin, simvastatin and pravastatin in plasma using GC 
with chemical ionization mass spectrometry has been described [70]. The analytes were 
isolated from plasma by SPE procedure which separated the lactone and acid forms of the 
drugs. The lactone forms were converted to the corresponding acid forms, which were 
subsequently derivatized by pentafluorobenzylation of the carboxyl group, and 
trimethylsilylation of the hydroxyl functions. The method has sufficient sensitivity for the 
analysis of clinical samples containing the drugs administered at therapeutic doses with 
recoveries between 79 and 90%. In another method, simvastatine and its acid form were 
derivatized with ferroceneboranic acid.  
Far to our knowledge since 2001 no method for determination of statin drugs in biological 
samples using gas chromatography has been published due to imprecise and time 
consuming derivatization procedures which is an unavoidable step in analysis of statin 
molecules and the biggest disadvantage of using this technique.  
3.4. Pharmacokinetic studies 
Since all HMG-CoA reductase inhibitors are given to the patients once daily, monitoring 
plasma concentrations over a period of 24 hours is necessary. In all published papers 
monitoring plasma concentration levels were performed at least over 24 hours, except in 
references [74, 89] were the blood samples were collected at various time points during a 
period of 12 hours after a single oral dose of rosuvastatin and atorvastatin, respectively. 
Also, in pharmacokinetic and bioavailability study of simvastatin in healthy volunteers and 
moderately hyperlipemic patients' drug plasma concentrations were monitored during 12 
hours [96]. In the most of investigations pharmacokinetic parameters of statins were 
investigated after only one pharmaceutical tablet dosage.  
Pharmacokinetic parameters of rosuvastatin have been investigated after single doses of 5, 
10 and 20 mg [79]. The peak plasma levels obtained from this study were 8.32, 14.8 and 20.1 
ng/mL, respectively. It was found that plasma exposure to rosuvastatin appeared increasing 
dose-proportionally and the plasma elimination half-lives were prolonged with increased 
doses. Not so many methods for determination of statins in human urine have been 
developed. The SPE-LC/MS/MS method was successfully applied to quantify the 
pitavastatin concentration in plasma and urine which were collected from Chinese 
volunteers [84]. The urinary excretion ratio of pitavastatin accounted for less than 0.6%, 
which suggested that pitavastatin was not excreted primarily by kidney. Quite similar data 
were obtained using LLE-LC/MS/MS method [88].  
Several above described bioanalytical assays have been used in bioequivalence studies of 
statin drugs. The pharmacokinetic parameters derived from drug plasma concentrations, 
including maximum plasma concentration, area under the plasma concentration-time curve 
from 0 h to the last measured data, area under the plasma concentration-time curve from 0 h  
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Analytes Matrix / 
Sample 
preparation 
Stationary phase Mobile phase Separation 
technique 
and 
Detection 
LOQ      Ref. 
ROS + metabolites,  
IS=deuterium labeled 
plasma Agilent Zorbax-SB 
Phenyl, Rapid 
Resolution HT (100 
x 2.1 mm, 3.5 μm) 
gradient elution
A: 0.1% glacial acetic acid 
in 10 % methanol in water 
B: 40% methanol in ACN 
HPLC 
ESI+ 
MS/MS 
MRM 
0.1– 0.5 
ng/mL  
74 
SIM, SIM acid  
IS= LOV, LOV acid 
plasma YMC ODS-A (50 x 
4.0 mm) 
ACN:5 mM ammonium 
acetate pH 4.5 (82:18) 
HPLC 
APCI/ESI-
/ESI+ 
MS/MS 
MRM 
0.1  
ng/mL 
75 
FLU, VAL + metabolite, 
CLT 
IS=candesartan cilexetil 
plasma Waters Atlantis 
dC18 (100 x 3.9, 3 
μm) 
gradient elution
A: ACN, 0.01% formic acid, 
10 mM ammonium formate
B: 0.01% formic acid, 10 
mM ammonium formate 
pH 4.1   
HPLC 
UV 229, 254, 
236 nm 
FD 254, 378 
nm 
UV:  
31-85 
μg/mL  
FD:  
10-20 
μg/mL 
76 
ROS 
IS=hydrochlorothiazide 
plasma Agilent Zorbax 
XDB-C18 (150 x 4.6 
mm, 5 μm) 
methanol:water (75:25), pH 
6.0 with ammonia 
HPLC 
ESI- 
MS/MS 
MRM 
0.02 
ng/mL 
79 
SIM, SIM-acid, ATO + 
metabolites  
IS=deuterium labeled 
serum Waters Acquity 
UPLCTM BEH C18 
(100 x 2.1 mm, 1.7 
μm) 
gradient elution
A: ACN 
B: 0.5 mM ammonium 
acetate buffer pH 4.0 
UPLC 
ESI+ 
MS/MS 
SRM 
0.09–
4.38 
nM 
83 
PIT 
IS=ROS 
plasma, urine Shimadzu Shim-
pak VP-ODS (150 x 
4.6 mm, 5 μm) 
methanol:water:formic acid 
(75:25:0.05) 
HPLC
ESI+ 
MS/MS 
SRM
0.08  
ng/mL 
84 
PRA + metabolites, FFA
IS=triamcinolone 
plasma Phenomenex 
Synergi Max-RP 
(150 x 2 mm, 4 μm)
ACN:methanol:5 mM 
ammonium acetate buffer 
pH 4.5 (30:30:40)  
HPLC
ESI+ 
MS/MS 
MRM 
0.05– 
0.5 
ng/mL 
85 
ATO + metabolites 
IS=deuterium labeled 
serum Waters BEH C18
(100 x 2.1 mm, 1.7 
μm) 
gradient elution
A: ACN 
B: 0.5 mM ammonium 
acetate pH 4.0 
UPLC 
ESI+ 
MS/MS 
SRM 
0.08-
0.66 
nM 
86 
FLU, VAL + metabolite, 
CLT 
IS=candesartan cilexetil 
plasma Waters Acquity 
UPLCTM BEH C18 
(50 x 2.1 mm, 1.7 
μm) 
gradient elution
A: 10 mM ammonium 
formate, 0.01% formic acid 
B: ACN, 10 mM 
ammonium formate, 0.01% 
formic acid, pH 4.1   
UPLC 
UV 220 nm 
20-110 
μg/mL 
87 
PIT, PIT-lacton 
IS=racemic i-prolact 
plasma, urine Thermo BDS 
Hypersil C8 (50 x 
2.1 mm, 3 μm) 
methanol:0.2% acetic acid 
in water (70:30) 
HPLC 
ESI+ 
MS/MS 
MRM
1 
ng/mL 
88 
LOV-lovastatin, SIM-simvastatin, PRA-pravastatin, FLU-fluvastatin, ATO-atorvastatin, ROS-rosuvastatin, PIT-
pitavastatin, VAL-valsartan, FFA-fenofibric acid, CLT-chlorthalidone, ACN-acetonitrile, IS-internal standard 
Table 3. Analytical methods for the determination of statins in biological samples 
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to the infinity, the time to reach peak concentration, the apparent elimination rate constant, 
showed that there was no statistically significant difference between two investigated 
pharmaceutical formulations [72, 73]. 
Not so many chromatographic methods have been developed for the quantification of 
HMG-CoA reductase inhibitors in combination with their metabolites. They undergo 
quite extensive first-pass metabolism during witch active and inactive metabolites are 
produced. The actual plasma concentrations of both parent compounds and metabolites 
are of major interest in pharmacokinetics studies. Therefore, analytical methods for 
simultaneous determination of statins and their metabolites are quite valuable. Although 
simultaneous determination of statins and their metabolites was considered being 
difficult owing to the different polarities of the analytes, several methods have been 
published.  
Recently, Apostolou and co-workers [75] published fast and fully automated LLE-
LC/MS/MS method, while Zhang and co-workers [82] presented a high-throughput salting-
out assisted LLE-LC/MS/MS method for simvastatin in lactone and acid form. Both of 
methods were very fast with analytical runs less than two min and fairly sensitive with LOQ 
values around 0.1 ng/mL. Nováková and co-workers [83] have developed fast selective and 
reliable SPE-UPLC/MS/MS method for simultaneous determination of simvastatin and 
atorvastatin as well as their active and inactive metabolites. The main advantage of the 
method was applicability of the method for determination of two clinically widely used 
statins using one sample preparation procedure and one chromatographic run, while the 
main limitation of study was slightly higher LOQ value obtained for simvastatin in open-
ring hydroxy acid form. 
More recently Vlčková and co-workers [86] have presented a new MEPS-UPLC method for 
determination of atorvastatin and its metabolites, faster and more sensitive comparing to 
previously published ones. A simple, fast and reproducible method for determination of 
rosuvastatin and metabolites in human plasma has been described [74]. The major 
advantages of the method were the requirement for small plasma volume and simple 
sample preparation procedure, protein precipitation. The major limitation of method was its 
inability to determine N-desmethyl rosuvastatin in the patient samples although its LOQ 
was quite low, 0.5 ng/mL. The patients included in the study took a single dose of 
rosuvastatin at 20 mg. N-desmethyl rosuvastatin is a minor metabolite that is present in 
much lower concentrations than rosuvastatin. Therefore, the authors anticipate that the 
methods should be sensitive enough to measure its concentration in patients receiving 
rosuvastatin on a routine basis.  
A sensitive and accurate procedure based on solid-phase extraction coupled at-line to a 
LC/MS/MS for determination of pravastatin and its two metabolites in human plasma has 
been presented [85]. Optimized and validated LLE-LC/MS/MS method for determination of 
pitavastatin and its lacton form in human plasma as well as in urine is described [88].  
 
Chromatography – The Most Versatile Method of Chemical Analysis 412 
Furthermore, a LC/MS/MS method for separation of fluvastatin from its threo isomers 
metabolites to support a bioequivalence study has been developed [97].       
The advantage of the methods for simultaneous determination of several co-administered 
drugs is that the one sample preparation and one chromatographic run are required for 
monitoring therapeutic levels of several drugs. Therefore, these methods could be useful in 
daily routine sample handling, when many samples from patients taking different drugs 
together with HMG-CoA reductase inhibitors are analyzed in clinical laboratories. Recently, 
several chromatographic methods have been developed for the quantification of statin 
drugs in combination with other drugs, most of them are commonly used in treatment of 
cardiovascular disease: atenolol, spironolactone, glibenclamide [61], metoprolol succinate 
[72], valsartan and chlorthalidone [76, 87], timolol maleate, diclofenac sodium [81], 
fenofibric acid [85], ezetimibe [91], ceftriaxone [92], acetylsalicylic acid [94], amlodipine [98]  
and losartan, atenolol, acetylsalicylic acid [99]. 
Recently, several papers were published regarding prediction of statins’ pharmacokinetics. 
In our work the usefulness of reversed-phase high performance chromatography in building 
models that would allow the prediction of pharmacokinetics parameters of statins was 
evaluated [100]. In order to get better insight into the nature of their chromatographic 
behavior, the retention times were measured using octyl and octadecyl chromatographic 
columns. Obtained chromatographic data were compared with pharmacokinetic parameters 
predicted by use of 17 different computer programs. Significant correlations were found 
between chromatographic data and lipophilicity of statins. In addition, with the combine set 
of descriptors (chromatographic data, solubility, quantum chemical and topological indices) 
the highly significant correlations with pharmacokinetic parameters have been found, which 
confirms the utility of HPLC technique for prediction of pharmacokinetic behavior of statin 
drugs.  
In order to predict the bioavailability of statins, the association mechanism with 
phosphatidylcholine using immobilized artificial membrane high performance liquid 
chromatography technique was studied. Moreover, the thermodinamic driving forces for 
the statin molecules with phosphatidylcholine monolayers were analyzed in detail [101].  
4. Capillary electrophoresis 
Capillary electrophoresis (CE) is an alternative separation technique which is designed to 
separate species based on their size to charge ratio in an electric field in the interior of a 
small capillary filled with background electrolyte. Driving forces in CE are electrophoretic 
migration and the electro-osmotic flow (EOF). CE has become a useful tool in 
pharmaceutical analysis because of its advantages over other separation techniques, such as 
high resolution, high selectivity, simplicity, short analysis time, cost efficiency and low 
consumption of solvents and reagents [102]. Mainly employed CE modes for drug analysis 
are capillary zone electrophoresis (CZE) based on charge-to-mass ratio and micellar 
electrokinetic chromatography (MEKC) based on chromatographic partition of analytes 
between micelles and background electrolyte. MEKC is the most appropriate electrophoretic 
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technique for impurity profiling because the neutral compounds and charged components 
that have similar electrophoretic mobilities can be separated simultaneously [103]. CE is 
currently recommended in several pharmacopoeias. Principal advantage of CE over well-
established and widely used HPLC technique is its ability to deliver high efficiency in short 
analysis times [104]. However, CE methods proposed for the determination of statin drugs 
are scarce.  
CE has been applied for determination of pravastatin in fermentation broth in order to 
optimize its production in bioreactors [105]. Pravastatin is produced in two-step 
fermentation. In the first step, mevastatin is produced by P. citrinum, and in the second step, 
bioconverted to pravastatin by S. carbophylus. The method successfully separated 
pravastatin from interfering matrix, mevastatin and 6-epi pravastatin. Its determination in 
production media was also performed using two HPLC methods. All three proposed 
methods had runtimes under 1 min. However two HPLC methods, performed on a particle 
and a monolithic LC column had superior sensitivity compared to MEKC, with LOD around 
0.01 ng/mL, 0.2 ng/mL and 20 ng/mL, respectively.  
We have developed CZE method for determination of pravastatin in pharmaceutical 
dosage form [106]. Rapid migration of negatively charged pravastatin molecule was 
obtained in alkaline buffer by the application of electric field of 30 kV. The alkaline buffer 
generated strong EOF that enabled determination of a fully charged drug molecule within 
2.5 min. Pravastatin retention time is about 21 min in the assay procedure listed in 
European Pharmacopoeia (Ph. Eur.) using the HPLC with UV detection. Relatively short 
analysis time is the main advantage of the CZE method developed. Pravastatin is 
administered to patients in its active form as the hydroxy acid sodium salt. However, the 
drug exists in solution with its lactone equilibrium product reversibly formed at acidic 
pH. Pravastatin is also susceptible to an isomerization reaction which is relatively rapid 
[107]. The MEKC method was established to separate the drug and its degradation 
products in acidic media. Introduction of sodium dodecyl sulphate (SDS) in the 
background electrolyte solution plays a key role in the separation of negatively charged 
and neutral species. The proposed method allows baseline separation of pravastatin, C-6 
epimer of pravastatin and their corresponding lactone forms that appear as 
interconversion products depending on the pH value. The migration times of degradation 
compounds ranged from 2.8 to 6.2 min. The above mentioned interconversion compounds 
of pravastatin represent its related impurities defined in Ph. Eur. and are also potential 
biotransformation products. CE has also been applied to the screening of anionic 
impurities in bulk drug [108]. 
The application of CE to rapidly quantitate lovastatin production levels by Aspergillus 
terreus mutants has been described [109]. The fermentation broths of thousands of 
mutated strains were efficiently and inexpensively screened for increased lovastatin 
production by the developed high-throughput method. Determination of lovastatin in the 
presence of its oxidation products after exposure to an oxidative atmosphere has been 
carried out using CE technique [110]. The method developed is suitable for the routine 
analysis of lovastatin. 
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The quantitative analysis of lovastatin in urine samples based on CE has significance for the 
control of clinical therapy [111]. The concentration sensitivity is poor in CE because of the 
short optical path length limited by the inner diameter of the capillary and small volume of 
sample injected. Such low sensitivity has hampered the use of this method in clinical drug 
monitoring. However, the sensitivity was enhanced by using a simple stacking method for 
the determination of trace lovastatin in biologic fluids.  
The CZE method was developed for the separation and determination of lovastatin as active 
ingredient in the red yeast rice product [112]. Prior to determination, lovastatin was 
extracted from capsule by ethanol. In this study, high pH (10.5) was selected in order to 
convert lovastatin to its acidic form completely. However, earlier reported studies revealed 
that lovastatin and lovastatin hydroxy acid are the two main components which contribute 
to up to 90% of the total quantity of monacolins in the read yeast rice [13]. Hence, the main 
disadvantage of the proposed CE method is that the content of the main components 
contributing to the pharmacology effect in red yeast rice supplement was not determined 
individually.  
Only one CE method for the analysis of simvastatin is available till date [113]. This method 
was developed for the quanitication of both lovastatin and simvastatin in pharmaceutical 
dosage forms. 
In the literature, CZE method has been reported for determination of atorvastatin [114]. The 
separation was optimized on capillary, but it was further miniaturized to a microchip 
platform with linear imaging UV detection. Even though CE is a rather good alternative for 
evaluation of impurity profile and enantiomeric purity of a drug, it is not enough applied. 
Therefore, we have developed a new MEKC method for separation and simultaneous 
quantitation of atorvastatin and its related substances diastereomer-atorvastatin, desfluoro 
atorvastatin, atorvastatin methyl ester and atorvastatin lactone [115]. The separation was 
carried out in an extended light path capillary in order to improve sensitivity at applied 
voltage of 30 kV using a background electrolyte consisting of 10 mM sodium tetraborate 
buffer pH 9.5, 50 mM SDS and 20% (v/v) methanol. Separation of neutral compounds from 
each other requires partitioning into charged micelles that migrate at a different rate from 
the EOF.  The addition of methanol to the running buffer resulted in a very effective choice 
to achieve resolution between the peaks of charged substances adjacent to atorvastatin as 
well as the peaks of neutral drug-related substances. Linear calibration curves were 
established over the concentration range 100-1200 μg/mL for atorvastatin and 1.0-12.5 
μg/mL for related substances. The applicability of the proposed MEKC method to the assay 
of atorvastatin in the presence of its related substances was investigated by analyzing the 
bulk drug provided by different manufacturers and various commercial formulations. The 
use of very low volumes of electrolyte (μL) and samples (nL) make the new MEKC 
procedures very interesting for determination of atorvastatin, purity evaluation and 
quantification of drug-related substances in a single analysis. The drawback of the proposed 
MEKC method is lower sensitivity compared to one obtained by RP-LC method for the 
same related substances [45]. The published UPLC method for simultaneous determination 
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of atorvastatin and fenofibrate has better sensitivity and runtime of 3 min but the linearity, 
LOQ and LOD was established only for atorvastatin lactone [43].  
CE method was also developed for the separation and simultaneous determination of 
atorvastatin and amlodipine in their combination formulations [116]. Degradation products 
produced as a result of stress studies did not interfere with the detection of both drugs and 
the assay can thus be considered stability indicating. 
The CE method was developed for the enantiomeric purity determination of fluvastatin 
enantiomers [117]. Its principle involves the formation of diastereoisomer complexes after 
addition of neutral cyclodextrin to the running buffer. Fluvastatin enantiomers were 
separated on an uncoated fused silica with 100 mM borate solution containing 30 mg/mL of 
(2-hydroxypropyl)-β-cyclodextrin as running buffer and fenoprofen as an internal standard. 
The limit of detection and quantification for (+)-3R, 5S and (-)-3S, 5R-fluvastatin were 1.5 
μg/mL and 2.5 μg/mL, respectively. Compared to chiral LC separations, CE analyses are 
cheaper (no chiral column, no solvent, low consumption of chiral selector) and peak 
efficiencies are higher by one order of magnitude. 
There is only one CE method for quantification of rosuvastatin [118]. Currently, for 
rosuvastatin only a limited number of analytical methods are reported in literature. This is 
due to the fact that rosuvastatin is a new statin introduced in the EU in 2002 and approved 
in the US in 2003.  
Using neutral β-cyclodextrin as chiral selector, the CZE method has been established for the 
chiral separation of pitavastatin calcium enantiomers [119]. Pitavastatin is a novel statin that 
potentially represents an important addition to the cardiovasculary therapy. In view of this, 
simple and efficient capillary electrophoretic methods for the determination of rosuvastatin 
and pitavastatin are highly required.  
5. Simultaneous analysis of statin drugs 
Since statins differ in their structure, analytical methods for their determination are 
developed individually. In fact, since statin drugs are never co-administered together 
during treatment of hyperlipimidemia, some authors even argued that there is no need for 
their simultaneous analysis. However, lately papers have been published that propose 
analytical methods that enable separation, identification and quantitative determination for 
two and even all six statins simultaneously in a single run. This kind of method would allow 
determination of any statin available on the market without the need of developing a new, 
separate, individual method for each statin, and could by used for simultaneous analysis of 
pharmaceutical dosage forms or in routine clinical monitoring.   
A HPTLC method was published using precoated silica gel 60F 254 aluminum sheets and 
detection carried out at 239, 238 and 310 nm for determination of simvastatin, pravastatin 
and rosuvastatin in tablet dosage forms, respectively [120]. Far to our knowledge first 
HPLC-PDA method for simultaneous analysis of atorvastatin, lovastatin, pravastatin, 
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rosuvastatin and simvastatin was reported for determination in pharmaceutical 
formulations and in vitro metabolism studies [121]. An uncommon gradient method using 3 
mobile phase reservoirs was employed. Downside of the method is relatively long analysis 
time of 40 minutes and fluvastatin not being included in the simultaneous analysis.  
An interesting method for pharmaceutical analysis of atorvastatin, simvastatin and 
lovastatin using a charged aerosol detector (CAD) was published [122]. CAD is a universal 
detector for HPLC that operates regardless of the physiochemical and spectral properties of 
non-volatile analytes. It can provide data complementary to UV or MS detectors. The eluent 
from the HPLC column is first nebulized and then charged. A highly sensitive electrometer 
generates a signal proportional to the analyte quantity. Although CAD is considered as a 
non-linear detector, the authors found a perfectly linear response (R > 0.9995). Sensitivity of 
the CAD detector was two folds greater then the UV detector; LOD of atorvastatin 
measured with UV and CAD detectors was 0.17 μg/mL and 0.08 μg/mL, respectively. 
A HPLC-UV method for quantification of rosuvastatin, atorvastatin, fluvastatin, lovastatin 
and simvastatin and four fibrates in pharmaceutical dosage forms was developed [123]. In 
this paper a simple GC-FID method was also proposed for identification of atorvastatin, 
lovastatin and simvastatin along four fibrates.  
Two stability-indicating HPLC methods for quantitative determination of pravastatin, 
fluvastatin, atorvastatin and rosuvastatin in pharmaceuticals were developed [124].  
Methods for their simultaneous determination in biological samples could provide easy 
quantification of drug level in human plasma without changes in the chromatographic 
procedures for individual statin. Despite the fact that these drugs seem to be structurally 
similar, development of the method for their simultaneous determination in complex 
biological samples is quite challenging task as they differ significantly in terms of solubility, 
polarity, stability as well as optic characteristics. Until now several analytical methods have 
been developed for the determination of statins in biological samples simultaneously, 
simvastatin and atorvastatin [83], rosuvastatin and atorvastatin [90], simvastatin, 
pravastatin, rosuvastatin and atorvastatin [92]. 
Investigation of statins in the environment has become an important issue in the last years due 
to their large worldwide consumption and their potential adverse effects on animal and 
human health. Three different preconcentration techniques including solid phase extraction, 
dispersive liquid–liquid microextraction and stir-bar sorptive extraction have been optimized 
and compared for the simultaneous analysis of statin drugs in wastewater and river water 
samples by HPLC coupled to quadrupole-time-of-flight mass spectrometry [125]. 
Due to low sensitivity of CE, three on-line preconcentration strategies were investigated for 
the analysis of charged and neutral statins by MEKC [126]. A background electrolyte 
consisting of 20 mM ammonium bicarbonate buffer (pH 8.50) and 50 mM SDS was used for 
the separation of all statin molecules including mevastatin. The methods were applied for 
the analysis of statin analytes in wastewater samples. The more frequently prescribed statins 
are of environmental concern. Consequently, sensitive methods for investigation of 
distribution of statin drugs in the environment are very valuable. 
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We have introduced a universal MEKC method with diode-array detection for the 
simultaneous and short-time analysis of lovastatin, simvastatin, pravastatin, fluvastatin, 
atorvastatin and rosuvastatin in a single run [127]. Base hydrolysis was used to open lactone 
ring of lovastatin and simvastatin, administered as lactone prodrugs, in order to transform 
these compounds to the corresponding acid forms before analysis. This approach offered 
shorter analysis time due to a decrease of the migration times of negatively charged statin 
drugs in comparison to neutral lactone forms. The first step in CE method development for 
optimizing the separation of ionisable statin molecules was the selection of the buffer pH, 
which determined the extent of ionization and mobility of each drug. As reported in the 
literature, statins with β-hydroxy acid forms have pKa values between 4.1 and 4.6 [128] and 
statin molecules are completely in anionic forms above pH 6. Surfactant was added to the 
electrolyte to improve the selectivity of the separation. With SDS, negatively charged statins 
molecules were not strongly attracted to the micelles, and drug molecules were separated as 
a result of differences in their electrophoretic mobilities and lipophilicity. The addition of an 
organic modifier in the presence of SDS in the electrolyte solution played a key role in the 
separation of statin molecules. The addition of an organic modifier changes the selectivity 
and migration times due to the change in electrolyte viscosity, dielectric constant and the 
zeta potential. The SDS micelles and methanol in the concentration of 10% v/v added to the 
borate buffer (pH 9.5) were employed in order to reduce the analysis time while 
maintaining good resolution between all six statins. The new developed MEKC method 
enabled a powerful separation and simultaneous, simple and rapid determination of six 
statins in 5 min (Figure 3). The method developed was successfully applied to analysis of six 
different pharmaceutical dosage forms of statin drugs. 
 
Figure 3. Electropherogram of a simultaneous analysis of statins 
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6. Conclusion 
Development of the analytical methods for identification, purity evaluation and 
quantification of statin drugs has received a great deal of attention in the field of 
pharmaceutical analysis in recent years. This review includes trends and advances in 
separation methods developed for the analysis of statin molecules with different physical 
and chemical properties. The chapter surveys the application of chromatographic techniques 
for the determination of statins in pharmaceutical dosage forms and biological samples.  
Stability indicating methods and papers describing impurity profiling are discussed in this 
review. Special emphasis is given to sample preparation as unavoidable and delicate step in 
bioanalitical methods for quantification of statins and their metabolites. The hyphenated 
technique that incorporates the efficient separation using liquid chromatography and 
sensitive detection by mass spectrometry has become an indispensable tool for quantification 
of statins in biological fluids and pharmacokinetic studies. Methods describing simultaneous 
analysis of different statins as well as drugs in combined pharmaceutical products and other 
co-administered drugs in therapy of cardiovascular disease are also described. The 
application of capillary electrophoresis as alternative separation technique for statins is 
considered and compared with chromatographic methods. 
The use of statin drugs has augmented in recent years and is expected to increase further in 
the years ahead because high cholesterol and cardiovascular diseases are being diagnosed 
more frequently. Therefore, the development of new analytical methods for commercially 
available statins as well as novel upcoming statin drugs will be a future challenging task for 
many analysts. 
Author details 
Biljana Nigović, Ana Mornar and Miranda Sertić 
University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia 
Acknowledgement 
This work was supported through Grant No. 0061117-1240 (Investigation of new methods in 
analysis of drugs and bioactive substances) from the Ministry of Science, Education and 
Sports of the Republic of Croatia. 
7. References 
[1] Mc Taggart F, Jones P (2008) Effects of Statins on High-Density Lipoproteins: A Potential 
Contribution to Cardiovascular Benefit. Cardiovasc. Drugs Ther. 22: 321-338. 
[2] Endo A, Kuroda M, Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of 
cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 29: 1346-1348. 
[3] Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J (2004) Effects of statins on 
vascular structure and function: a systematic review. Am. J. Med. 117: 775-790.  
A Review of Current Trends and Advances in Analytical Methods  
for Determination of Statins: Chromatography and Capillary Electrophoresis 419 
[4] Bu D, Griffin G, Lichtman AH (2011) Mechanisms for the anti-inflammatory effects of 
statins. Curr. Opin. Lipidol. 22: 165-170. 
[5] A.W. Alberts, J. Chen, G. Kuron, V. Hunt, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, 
E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Alberts-Schonberg, O. 
Hensens, J. Hirshchfield, K. Hoogsteen, J. Liesch, J. Springer (1980) Mevinolin: A highly 
potent competitive inhibitor of hydroxymethyl glutaryl-coenzyme A reductase and a 
cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77: 3957–3961. 
[6] Endo A (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus 
sp. J. Antibiot. 32: 852–854. 
[7] Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of 
statins: an update. Fundam. Clin. Pharmacol. 19: 117-125. 
[8] Corsini A, Maggi FM and Catapano AL (1995) Pharmacology of competitive inhibitors of 
HMG-CoA reductase. Pharmacol. Res. 34: 9-27. 
[9] Jemal M, Xia YQ (2000) Bioanalytical method validation design for the simultaneous 
quantitation of analytes that may undergo interconversion during analysis. J. Pharm. 
Biomed. Anal. 23: 813-827. 
[10] Nirogi R, Mudigonda K, Kandikere V (2007) Chromatography-Mass Spectrometry 
Methods for the Quantitation of Statins in Biological Samples. J. Pharm. Biomed. Anal. 
44: 379-387. 
[11] Yang DY, Hwang LS (2006) Study on the Conversion of Three Natural Statins from 
Lactone Forms to their Corresponding Hydroxy Acid Forms and their Determination in 
Pu-Erh Tea. J. Chromatogr. A. 119: 277-284. 
[12] Huang Z, Xu Y, Li Y, Wang Y (2010) Conversion Investigation for Lovastatin and Its 
Derivates by HPLC. J. Chromatogr. Sci. 48: 631-636. 
[13] Li Y, Zhang F, Wang Z, Hu Z (2004) Identification and Chemical Profiling of 
Monacolins in Red Yeast Rice Using High-Performance Liquid Chromatography with 
Photodiode Array Detector and Mass Spectrometry. J. Pharm. Biomed. Anal. 3: 1101-
1112. 
[14] Huang HN, Hua YY, Bao GR, Xie LH (2006) The Quantification of Monacolin K in Some 
Red Yeast Rice from Fujian Province and the Comparison of the Other Product, Chem 
Pharm Bull 54: 687-689. 
[15] Li YG, Liu H, Wang ZT (2005) A Validated Stability Indicating HPLC with Photodiode 
Array Detector (PDA) Method for the Stress Tests of Monascus purpureus Fermented 
Rice, Red Yeast Rice, J. Pharm. Biomed. Anal. 39: 82-90.  
[16] Song F, El-Demerdash, Lee SSH, Smith RE (2012) Fast Screening of Lovastatin in Red 
Yeast Rice Products by Flow Injection Tandem Mass Spectrometry. J. Pharm. Biomed. 
Anal. 57: 76-81.  
[17] Novakova L, Šatinsky D, Solich P (2008) HPLC Methods for the Determination of 
Simvastatin and Atorvastatin, Trends Anal. Chem., 27(4):352-367. 
[18] Ortega Markman BE, Pires Rosa PC, Walter Koschtchak MR (2010) Assessment of the 
Quality of Simvastatin Capsules from Compounding Pharmacies. Rev. Saude Publica 
44: 1055-1062. 
 
Chromatography – The Most Versatile Method of Chemical Analysis 420 
[19] Hill SW, Varker AS, Karlage K, Myrdal PB (2009) Analysis of Drug Content and Weight 
Uniformity for Half-Tablets of 6 Commonly Split Medications. J. Manag. Care Pharm. 
15: 253-261. 
[20] Ali H, Nazzal S (2009) Development and Validation of a Reversed-Phase HPLC Method 
for the Simultaneous Analysis of Simvastatin and Tocotrienols in Combined Dosage 
Forms. J. Pharm. Biomed. Anal. 49: 950-956. 
[21] Zhao X, Guofei L, Zhang L, Tao X, Guan T, Hong M, Tang X (2010) Preparation and 
evaluation of nicotinic acid sustained-release pellets combined with immediate release 
simvastatin. Int. J. Pharm. 400: 42-48. 
[22] Ozaltin N, Ucakturk E (2007) Simultaneous Determination of Ezetimibe and Simvastatin 
in Pharmaceutical Formulation by Dual-Mode Gradient LC. Chromatographia 66: 87-91. 
[23] Oliveira PR, Barth T, Todeschni V, Dalmora SL (2007) Simultaneous Liquid 
Chromatographic Determination of Ezetimibe and Simvastatin in Pharmaceutical 
Products. J. AOAC Int. 90: 1566-1572. 
[24] Chaudhari BG, Patel NM, Shah PB (2007) Stability-Indicating Reversed-Phase Liquid 
Chromatographic Method for Simultaneous Determination of Simvastatin and 
Ezetimibe from their Combination Drug Products. J. AOAC Int. 90: 1242-1249. 
[25] Hefnawy M, Al-Omar M, Julkhuf S (2009) Rapid and Sensitive Simultaneous 
Determination of Ezetimibe and Simvastatin from their Combination Drug Products by 
Monolithic Silica High-Performance Liquid Chromatographic Column. J. Pharm. 
Biomed. Anal. 50: 527-534. 
[26] Bertacche V, Milanese A, Nava D, Pini E, Stradi R (2007) Structural Elucidation of an 
Unknown Simvastatin By-product in Industrial Synthesis Starting from Lovastatin. J. 
Pharm. Biomed. Anal. 45: 642-647. 
[27] Plumb RS, Jones MD, Rainville P, Castro-Perez JM (2007) The Rapid Detection and 
Identification of the Impurities of Simvastatin Using High Resolution sub 2 microm 
Particle LC Coupled to Hybrid Quadrupole Time of Flight MS Operating with 
Alternating High-low Collision Energy. J. Sep. Sci. 30: 2666-2675. 
[28] Plumb RS, Jones MD, Rainville PD, Nicholson JK (2008) A Rapid Simple Approach to 
Screening Pharmaceutical Products Using Ultra-Performance LC Coupled to Time-of-
Flight Mass Spectrometry and Pattern Recognition. J. Chromatogr. Sci. 46: 193-198. 
[29] Reddy GV, Kumar AP, Reddy BV, Sreeramulu J (2009) Application of Ion-Trap Mass 
Spectrometry for Identification and Structural Determination of an Unknown Impurity 
in Simvastatin. Pharmazie 64: 638-641. 
[30] Bhatia MS, Jadhav SD, Bhatia NM, Choudhari PB, Ingale KB (2011) Synthesis, 
Characterization and Quantification of Simvastatin Metabolites and Impurities. Sci. 
Pharm. 79: 601-614. 
[31] Campos-Lara M, Mendoza-Espinoza J (2008) Development of a Selective Extraction 
Method for Pravastatin Qantification in Tablets using HPLC with Ultraviolet Detection. 
J. Liq. Chromatogr. R. T. 31: 619-623. 
A Review of Current Trends and Advances in Analytical Methods  
for Determination of Statins: Chromatography and Capillary Electrophoresis 421 
[32] Kocijan A, Grahek R, Zupančić-Kralj L (2006) Identification of an Impurity in 
Pravastatin by Application of Collision-Activated Decomposition Mass Spectra. Acta 
Chim. Slov. 53: 464-468. 
[33] Onal A, Sagirli O (2006) Development of a Selective LC Method for the Determination 
of Pravastatin Sodium. Chromatographia, 64: 157-162. 
[34] Brain-Isasi, Requena C, Alvarez-Lueje A (2008) Stability study of Pravastatin Under 
Hydrolity Conditions Assessed by HPLC. J. Chil. Chem. Soc. 52: 1684-1688. 
[35] Mielcarek J, Grobelny P, Osmalek T (2009) Identification of Photoproducts of 
Fluvastatin in Solutions. J. Plan. Chromatogr. 22: 137-140. 
[36] Shirkhedkar AA, Surana SJ (2010) Development and Validation of a Reversed-Phase 
High-Performance Thin-Layer Chromatography-Densitometric Method for 
Determination of Atorvastatin Calcium in Bulk Drug and Tablets. J. AOAC, Int. 93: 798-
803. 
[37] Khedr A (2008) Stability-Indicating High-Performance Liquid Chromatographic Assay 
of Atorvastatin with Fluorescence Detection. J AOAC 90: 1547-1553. 
[38] Mustafa G, Azeem A, Ahmad FJ, Khan ZI, Shakeel F, Talegaonkar S (2010) Stability-
Indicating RP-HPLC Method for Analysis of Atorvastatin in Bulk Drug, Marketed 
Tablet and Nanoemulsion Formulation. J. Chil. Chem. Soc. 55: 184-188. 
[39] Mohammadi A, Rezanour N, Ansari Dogaheh M, Ghorbani Bidkorbeh F, Hashem M, 
Walker RB (2007) A Stabiliy-Indicating High Performance Liquid Chromatographic 
(JPLC) Assay for the Simultaneous Determination of Atorvastatin and Amlodipine in 
Commercial Tablets. J. Chromatogr B. 846: 215-221. 
[40] Vora DN, Kadav AA (2008) Validated Ultra HPLC Method for the Simultaneous 
Determination of Atorvastatin, Acetylsalicylic Acid and their Degradation Products in 
Capsules. J. L. Chromatogr. R. T. 31: 2821-2837. 
[41] Shah RP, Kumar V, Singh S (2008) Liquid Chromatography/Mass Spectrometric Studies 
on Atorvastatin and its Stress Degradation Products. Rapid Commun. Mass Spectrom. 
22: 613-622. 
[42] Kračun M, Kocijan A, Bastarda A, Grahek R, Plavec J, Kocjan D (2009) Isolation and 
Structure Determination of Oxidative Degradation Products of Atorvastatin. J. Pharm. 
Biomed. Anal. 50: 729-736. 
[43] Kadav AA, Vora DN (2008) Stability Indicating UPLC Method for Simultaneous 
Determination of Atorvastatin, Fenofibrate and their Degradation Products in Tablets. J. 
Pharm. Biomed. Anal. 48: 120-126. 
[44] Mornar A, Damic M, Nigovic B (2010) Separation, Characterization, and Quantification 
of Atorvastatin and Related Impurities by Liquid Chromatography-Electrospray 
Ionization Mass Spectrometry. Anal. Lett. 43: 2859-2871. 
[45] Petkovska R, Cornett C, Dimitrovska A (2008) Development and Validation of Rapid 
Resolution RP-HPLC Method for Simultaneous Determination of Atorvastatin and 
Related Compounds by Use of Chemometrics. Anal. Lett. 41: 992-1009. 
[46] Malenovic A, Jancic-Stojanovic B, Kostic N, Ivanovic D, Medenica M (2011) Impurities 
Retention in Micelaar Liquid Chromatography. Chromatography. 73: 993-998. 
 
Chromatography – The Most Versatile Method of Chemical Analysis 422 
[47] Panchal HJ, Suhagia BN (2010) Simultaneous Determination of Atorvastatin Calcium 
and Ramipril in Capsule Dosage Forms by High-Performance Liquid Chomatography 
and High-Performance Thin Layer Chromatography. J. AOAC Int. 93: 1450-1457. 
[48] Skirkhedkar AA, Surana SJ (2009) Simultaneous Densitometric TLC Analysis of 
Atorvastatin Calcium and Fenofibrate in the Bulk Drug and in Pharmaceutical 
Formulations. J. Planar Chromatogr. 22: 355-358. 
[49] Raja Rajeswai K, Sankar GG, Rao AL, Seshagiriraio JVLN (2006) RP-HPLC method for 
the Simultaneous Determination of Atorvastatin and Amlodipine in Tablet Dosage 
Form. Indian J. Pharm. Sci. 68: 275-277. 
[50] Nakarani NV, Bhatt KK, Patel RD, Bhatt HS (2007) Estimation of Atorvastatin Calcium 
and Fenofibrate in Tablets by Derivate Spectrophotometry and Liquid 
Chromatography. J. AOAC Int. 90: 700-705. 
[51] Sechachalam U, Kothapally CB (2008) HPLC analysis for simultaneous determination of 
atorvastatin and ezetimibe in pharmaceutical formulations. J. Liq. Chromatogr. R. T. 31: 
714-721. 
[52] Lincy J, Mathew G, Venkata RR (2008) Simultaneous Estimation of Atorvastatin and 
Ramipril by RP-HPLC and Spectroscopy. Pak. J. Pharm. Sci. 21: 282-284. 
[53] Sivakumar T, Manavalan R, Muralidharan C, Valliappan K (2007) An Improved HPLC 
Method with the Aid of a Chemometric Protocol: Simultaneous Analysis of Amlodipine 
and Atorvastatin in Pharmaceutical Formulations. J. Sep. Sci. 30: 3143-3153. 
[54] Londhe SV, Deshmukh RS, Mulgund SV, Jain KS (2011) Development and Validation of 
a Reversed-Phase HPLC Method for Simultaneous Determination of Aspirin, 
Atorvastatin Calcium and Clopidogrel Bisulphate in Capsules. Indian J. Pharm. Sci. 73: 
23-29. 
[55] Damle MS, Patole SM, Potale LV, Khodke AS (2010) A validated HPLC method for 
Analysis of Atorvastatin Calcium, Ramipril and Aspirin as the Bulk Drug and in 
Combined Capsule Dosage Forms. Pharmacie Globale 1: 1-5. 
[56] Kumar V, Shah RP, Singh S (2008) LC and LC-MS Methods for the Investigation of 
Polypills for the Treatment of Cardiovascular Diseases Part 1. Separation of Active 
Components and Classification of their Interaction/Degradation Products. J. Pharm. 
Biomed. Anal. 47: 508-515. 
[57] Mehta TN, Patel AK, Kulkarni GM,, Suubbaiah G (2005) Determination of Rosuvastatin 
in the Presence of its Degradation Products by a Stability-Indicating LC Method. J. 
AOAC Int, 88: 1142-1147. 
[58] Sane RT, Kamat SS, Menon SN, Inamdar SR, Mote MR (2005) Determination of 
Rosuvastatin Calcium in its Bulk Drug and Pharmaceutical Preparations by High-
Performance Thin-Layer Chromatography. J. Planar Chromatogr. 18: 194-198. 
[59] Varghese SJ, Ravi TK (2010) Determination of Rosuvastatin and Ezetimibe in a 
Combined Tablet Dosage form using High-Performance Column Liquid 
Chromatography and High-Performance Thin-Layer Chromatography. J. AOAC Int. 93: 
1222-1227. 
A Review of Current Trends and Advances in Analytical Methods  
for Determination of Statins: Chromatography and Capillary Electrophoresis 423 
[60] Gajjar AK, Shah VD (2010) Development and Validation of a Stability-Indicating 
Reversed-Phase HPLC Method for Simultaneous Estimation of Rosuvastatin and 
Ezetimibe from their Combination Dosage Forms. Eurasian J. Anal. Chem.. 5:.265-283. 
[61] Sultana N, Arayne MS, Iftikhar B (2008) Simultaneous Determination of Atenolol, 
Rosuvastatin, Spironolactone, Glibenclamide and Naproxen Sodium in Pharmaceutical 
Formulations and Human Plasma by RP-HPLC. J. of the Chin. Chem. Soc.. 55:1022-
1029. 
[62] Kumar/Satheesh NK, Baghyalakshmi J (2007) Determination and Quantification of 
Pitavastatin Calcium in Tablet Dosage Formulation by HPTLC Method. Anal. Lett. 40: 
2625-2632. 
[63] Panchal HJ, Suhagia BN, Patel NJ, Patel BH (2008) A Simple and Sensitive HPTLC 
Method for Quantitative Analysis of Pitavastatin Calcium in Tablets. J. Planar 
Chromatogr. 21: 267-270. 
[64] Kumar NS, Nisha N, Nirmal J, Sonali N, Bagyalakshmi J (2011) HPLC determination of 
pitavastatin calcium in pharmaceutical dosage forms, Pharm Anal Acta 2: 119 
doi:10.4172/2153-2435.1000119  
[65] Panchal HJ, Suhagia BN (2011) Stability-Indicating Liquid Chromatographic Method for 
Analysis of Pitavastatin Calcium in Tablet Dosage Forms. Acta Chromatogr. 23: 81-64. 
[66] Grobleny P, Viola G, Vedaldi D, Dall'Acqua F, Gliszczynska-Swiglo A, Mielcarek J 
(2009) Photostability of Pitavastatin – A Novel HMG-CoA Reductase Inhibitor. J. 
Pharm. Biomed. Anal. 50: 597-601. 
[67] Panchal H, Suhagia BN (2011) Simultaenous Determination and Validation of 
Pitavastatin Calcium and Ezetimibe in Binary Mixture by Liquid Chromatography. Int. 
J. Pharm. Tech. Research. 3: 2155-2161. 
[68] Gomas AR, Ram PR, Srinivas N, Sriramulu J (2010) Degradation Pathway for 
Pitavastatin Calcium by Validated Stability Indicating UPLC Method. Am. J. Anal. 
Chem. 2: 83-90. 
[69] Panchal HJ, Suhagia BN, Patel MM, Patel BH (2009) Estimation of Pitavastatin cCalcium 
in Tablet Dosage Forms by Column Liquid Chromatography and Ultraviolet 
Spectrophotometry. J. AOAC Int. 92: 158-165. 
[70] Ertürk S, Önal A, Çetin SM (2003) Analytical Methods for the Quantitative 
Determination of 3-hydroxy-3-methylglutaril Coenzyme A Reductase Inhibitors in 
Biological Samples. J. Chromatogr. B. 793: 193-205. 
[71] Farahani H, Norouzi P, Beheshti A, Sobhi HR, Dinarvand R, Ganjali MR (2009) 
Quantitation of Atorvastatin in Human Plasma using Directly Suspended Acceptor 
Droplet in Liquid–liquid–liquid Microextraction and High-performance Liquid 
Chromatography-ultraviolet Detection. Talanta. 80: 1001-1006. 
[72] Senthamil Selvan P, Pal TK (2009) Chromatography–tandem Mass Spectrometry 
Method for the Simultaneous Quantitation of Metoprolol Succinate and Simvastatin in 
Human Plasma. J. Pharm. Biomed. Anal. 49: 780-785. 
 
Chromatography – The Most Versatile Method of Chemical Analysis 424 
[73] Hamidi M, Zarei N, Shahbazi M-A (2009) A Simple and Sensitive HPLC-UV Method for 
Quantitation of Lovastatin in Human Plasma: Application to a Bioequivalence Study. 
Biol. Pharm. Bull. 32: 1600-1603.  
[74] Macwan JS, Ionita IA, Akhlaghi F (2012) A Simple Assay for the Simultaneous 
Determination of Rosuvastatin Acid, Rosuvastatin-5S-lactone, N-Desmethyl 
rosuvastatin in Human Plasma using Liquid chromatography-tandem Mass 
Spectrometry (LC-MS/MS). Anal. Bioanal.Chem. 402: 1217-1227. 
[75] Apostolou C, Kousoulos C, Dotsikas Y, Soumelas G-S, Kolocouri F, Ziaka A, Loukas YL 
(2008) An Improved and Fully Validated LC–MS/MS Method for the Simultaneous 
Quantification of Simvastatin and Simvastatin Acid in Human Plasma. J. Pharm. 
Biomed. Anal. 46: 771–779. 
[76] Gonzalez O, Iriarte G, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM (2009) 
Optimization and Validation of a SPE-HPLC-PDA-fluorescence Method for the 
Simultaneous Determination of Drugs Used in Combined Cardiovascular Therapy in 
Human Plasma. J. Pharm. Biomed. Anal. 50: 630-639. 
[77] Lv H, Sun J-G, Wang G-J, Zhu X-Y, Zhang Yi, Gu S-H, Liang Y, Sun J (2007) 
Determination of Pitavastatin in Human Plasma via HPLC-ESI-MS/MS and Subsequent 
Application to a Clinical Study in Healthy Chinese Volunteers. Clin. Chim. Acta. 386: 
25-30. 
[78] Trivedi RK, Kallem RR, Mullangi R, Srinivas NR (2005) Simultaneous determination of 
rosuvastatin and fenofibric acid in human plasma by LC–MS/MS with electrospray 
ionization: Assay development, validation and application to a clinical study. J. Pharm. 
Biomed. Anal. 39: 661-669. 
[79] Gao J, Zhong D, Duan X, Chen X (2007) Liquid Chromatography/negative Ion 
Electrospray Tandem Mass Spectrometry Method for the Quantification of Rosuvastatin 
in Human Plasma: Application to a Pharmacokinetic Study. J. Chromatogr. B. 856: 35-40. 
[80] Lan K, Jiang X, Li Y, Wang L, Zhou J, Jiang Q, Ye L (2007) Quantitative Determination of 
Rosuvastatin in Human Plasma by Ion Ppair Liquid–liquid Extraction Using Liquid 
Chromatography with Electrospray Ionization Tandem Mass Spectrometry. J. Pharm. 
Biomed. Anal. 44: 540-546. 
[81] Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, Khan AZ, Khan JA, Khan S (2011) 
Simultaneous Determination of Timolol Maleate, Rosuvastatin Calcium and Diclofenac 
Sodium in Pharmaceuticals and Physiological Fluids Using HPLC-UV. J. Chromatogr. 
B. 879: 3434- 3443. 
[82] Zhang J, Rodila R, Gage E, Hautman M, Fan L, King LL, Wu H, El-Shourbagy TA (2010) 
High-throughput Salting-out Assisted Liquid/liquid Extraction with Acetonitrile for the 
Simultaneous Determination of Simvastatin and Simvastatin Acid in Human Plasma 
with Liquid Chromatography. Anal. Chim. Acta. 661: 167-172. 
[83] Nováková L, Vlčková H, Šatínský D, Sadílek P, Solichová D, Bláha M, Bláha V, Solich P 
(2009) Ultra High Performance Liquid Chromatography Tandem Mass Spectrometric 
Detection in Clinical Analysis of Simvastatin and Atorvastatin. J. Chromatogr. B. 877: 
2093-2103. 
A Review of Current Trends and Advances in Analytical Methods  
for Determination of Statins: Chromatography and Capillary Electrophoresis 425 
[84] Di B, Su M-X, Yu F, Qu L-J, Zhao L-P, Cheng M-C, He L-P (2008) Solid-phase Extraction 
and Liquid Chromatography/tandem Mass Spectrometry Assay for the Determination 
of Pitavastatin in Human Plasma and Urine for Application to Phase I Clinical 
Pharmacokinetic Studies. J. Chromatogr. B. 868: 95-101. 
[85] Mertens B, Cahay B, Klinkenberg R, Streel B (2008) An Automated Method for the 
Simultaneous Determination of Pravastatin, 3-hydroxy Isomeric Metabolite, 
Pravalactone and Fenofibric Acid in Human Plasma by Sensitive Liquid 
Chromatography Combined with Diode Array and Tandem Mass Spectrometry 
Detection. J. Chromatogr. A. 1189: 493-502. 
[86] Vlčková H, Solichová D, Bláha M, Solich P, Nováková L (2011) Microextraction by 
Packed Sorbent as Sample Preparation Step for Atorvastatin and its Metabolites in 
Biological Samples-Critical evaluation. J. Pharm. Biomed. Anal. 55: 301-308. 
[87] Iriarte G, Gonzalez O, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM (2009) 
Validation of a Fast Liquid Chromatography–UV Method for the Analysis of Drugs 
Used in Combined Cardiovascular Therapy in Human Plasma. J. Chromatogr. B. 877: 
3045-3053. 
[88] Tian L, Huang Y, Jia Y, Hua L, Li Y (2008) Development and Validation of a Liquid 
Chromatography–tandem Mass Spectrometric Assay for Pitavastatin and its Lactone in 
Human Plasma and Urine. J. Chromatogr. B. 865: 127-132. 
[89] Macwan JS, Ionita IA, Dostalek M, Akhlaghi F (2011) Development and Validation of a 
Sensitive, Simple, and Rapid Method for Simultaneous Quantification of Atorvastatin 
and its Acid and Lactone Metabolites by Liquid Chromatography-tandem Mass 
Spectrometry (LC-MS/MS). Anal. Bioanal. Chem. 400: 423-433. 
[90] Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, Nasir F (2011) Simultaneous 
Determination of Rosuvastatin and Atorvastatin in Human Serum using RP-HPLC/UV 
Detection: Method Development, Validation and Optimization of Various Experimental 
Parameters. J. Chromatogr. B. 879: 557-563. 
[91] Khan IU, Kausar T, Ashfaq M, Sharif S (2010) Development and Validation of Liquid 
Chromatographic Method for the Simultaneous Estimation of Ezetimibe and Lovastatin 
in Human Plasma. J. Chil. Chem. Soc. 55: 461-464. 
[92] Sultana N, Arayne MS, Shahzad W (2010) Simultaneous Determination of Ceftriaxone 
Sodium and Statin Drugs in Pharmaceutical Formulations and Human Serum by RP-
HPLC. J. Chil. Chem. Soc. 55: 193-198. 
[93] Shen-Tu J, Xu X, Liu J, Hu X, Chen J, Wu L, Huang M, Zhou H (2009) Determination of 
Pitavastatin in Human Plasma by LC-MS-MS. Chromatographia. 69: 1041-1047.  
[94] Polagani SR, Pilli NR, Gandu V (2012) High Performance Liquid Chromatography Mass 
Spectrometric Method for the Simultaneous Quantification of Pravastatin and Aspirin 
in Human Plasma: Pharmacokinetic Application. J. Pharm. Anal. In press 
[95] Kotagiri H, Gannu R, Palem CR, Yamsani SK, Yamsani VV, Yamsani MR (2011) 
Simultaneous Determination of Glimepiride and Atorvastatin in Human Serum by 
High-performance Liquid Chromatography: Application to Pharmacokinetic Study. J. 
Liqu. Chromatogr. R. T. 34: 2420-2432. 
 
Chromatography – The Most Versatile Method of Chemical Analysis 426 
[96] Ahmad M, Qamar-Uz-Zaman M, Madni A, Usman M, Atif M, Akhtar N, Murtaza G 
(2011) Pharmacokinetic and Bioavailability Studies of Commercially Available 
Simvastatin Tablets in Healthy and Moderately Hyperlipidemic Human Subjects. J. 
Chem. Soc. Pak. 33: 49-54. 
[97] Taillon MP, Côté C, Furtado N, Garofolo F (2011) Potentially New Isobaric Metabolite of 
Fluvastatin Observed by LC-MS/MS During Incurred Sample Analysis. Bioanalysis. 3: 
1827-1835. 
[98] Yu Q, Hu ZY, Zhu FY, Zhu JH, Wan LL, Li Y, Guo C (2011) HPLC-MS-MS for the 
Simultaneous Determination of Atorvastatin and Amlodipine in Plasma of 
Hypertensive Patients. Chromatographia. 73: 257-262. 
[99] Bhatia NM, Gurav SB, Jadhav SD, Bhatia MS (2012) RP-HPLC Method for Simultaneous 
Estimation of Atorvastatin Calcium, Losartan Potassium, Atenolol, and Aspirin from 
Tablet Dosage form and Plasma. J. Liqu. Chromatogr. R. T. 35: 428-443 
[100] Mornar A, Damić M, Nigović B (2011) Pharmacokinetic Parameters of Statin Drugs 
Characterized by Reversed Phase High-performance Liquid Chromatography. Anal. 
Lett. 44: 1009-1020.  
[101] Sarr FS, André C, Guillaume YC (2008) Statins (HMG-coenzyme A Reductase 
Inhibitors)-biomimetic Membrane Binding Mechanism Investigated by Molecular 
Chromatography J. Chromatogr. B 868: 20-27.  
[102] Altria K, Marsh A, Sanger-van de Griend C (2006) Capillary Electrophoresis for the 
Analysis of Small-Molecule Pharmaceuticals. Electrophoresis 27: 2263-2282. 
[103] Terabe S (2009) Capillary Separation: Micellar Electrokinetic Chromatography. Annu. 
Rev. Anal. Chem. 2: 99-120. [104] Suntornsuk L (2007) Recent Advances of Capillary 
Electrophoresis in Pharmaceutical Analysis. J. Chromatogr. Sci. 45: 559-577. 
[105] Kocijan A, Grahek R, Bastrada A, Zupancic-Kralj L (2005) Fast Analysis of Pravastatin 
in Production Media. J. Chromatogr. B 822: 311-315. 
[106] Nigović B, Vegar I (2008) Capillary Electrophoresis Determination of Pravastatin and 
Separation of Its Degradation Products. Croat. Chem. Acta. 81: 615-622. 
[107] Mulvana D, Jemal M, Pulver SC (2000) Quantitative Determination of Pravastatin and 
its Biotransformation Products in Human Serum by Turbo Ion Spray LC/MS/MS. J. 
Pharm. Biomed. Anal. 23: 851-866. 
[108] Nair JB, Izzo CG (1933) Anion Screening for Drugs and Intermediates by Capillary Ion 
Electrophoresis. J. Chromatogr. A 640: 445-461. 
[109] Kittell J, Borup B, Voladari R, Zahn K (2005) Parallel Capillary Electrophoresis for the 
Quantitative Screening of Fermentation Broths Containing Natural Products. Metab. 
Eng. 7: 53-58. 
[110] Javernik Rajh S, Kreft S, Štrukelj B, Vrečer F (2003) Comparison of CE and HPLC 
Methods for Determining Lovastatin and Its Oxidation Products after Exposure to an 
Oxidative Atmosphere. Croat. Chem. Acta 76:263-268. 
[111] Li M, Fan LY, Zhang W, Cao CX (2007) Stacking and Quantitative Analysis of 
Lovastatin in Urine Samples by the Transient Moving Chemical Reaction Boundary 
Method in Capillary Electrophoresis. Anal. Bioanal. Chem. 387: 2719-2725. 
A Review of Current Trends and Advances in Analytical Methods  
for Determination of Statins: Chromatography and Capillary Electrophoresis 427 
[112] Li M, Fan LY, Zhang W, Sun J, Cao CX (2007) Quantitative Analysis of Lovastatin in 
Capsule of Chinese Medicine Monascus by Capillary Zone Electrophoresis with UV–vis 
Detector. J. Pharm. Biomed. Anal. 43: 387-392.  
[113] Srinivasu MK, Raju AN, Reddy GO (2002) Determination of Lovastatin and 
Simvastatin in Pharmaceutical Dosage Forms by MEKC. J. Pharm. Biomed. Anal. 29: 
715-721. 
[114] Guihen E, Sisk GD, Scully NM, Glennon JD (2006) Rapid Analysis of Atorvastatin 
Calcium Using Capillary Electrophoresis and Microchip Electrophoresis. 
Electrophoresis 27: 2338-2347.  
[115] Nigović B, Damić M, Injac R, Kočevar Glavač N, Štrukelj B (2009) Analysis of 
Atorvastatin and Related Substances by MEKC. Chromatographia 69: 1299-1305. 
[116] Hefnawy MM, Sultan M, Al-Johar H (2009) Development of Capillary Electrophoresis 
Technique for Simultaneous Measurement of Amlodipine and Atorvastatin from Their 
Combination Drug Formulations. J. Liq. Chromatogr. Relat. Technol. 32: 2923-2942. 
[117] Trung TQ, Dung PT, Hoan NN, Kim DJ, Lee JH and Kim KH (2008) Chiral Separation 
of Fluvastatin Enantiomers by Capillary Electrophoresis. Arch. Pharm. Res. 31: 1066-
1072. 
[118] Süslü İ, Çelebier M, Altinöz S (2007) Determination of Rosuvastatin in Pharmaceutical 
Formulations by Capillary Zone Electrophoresis. Chromatographia 66: S65-S72. 
[119] Cheng X, Wang L, Yang G, Cheng J, Zhang Y (2010) Chiral Separation of Pitavastatin 
Calcium Enantiomers by Capillary Zone Electrophoresis. Chin. J. Chrom. 28: 1089-1093.  
[120] Chaduhari BG, Patel NM, Shah PB (2007) Determination of Simvastatin, Pravastatin 
Sodium and Rosuvastatin Calcium in Tablet Dosage Forms by HPTLC. Indian J. Pharm. 
Sci 69: 130-132. 
[121] Pasha K, Muzeeb S, Basha SJS, Shashikumar D, Mullangi R, Srinivas N (2006) Analysis 
of Five HMG-CoA Reductase Inhibitors- Atorvastatin, Lovastatin, Pravastatin, 
Rosuvastatin and Simvastatin: Pharmacological, Pharmacokinetic and Analytical 
Overview and Development of a New Method for use in Pharmaceutical Formulations 
Analysis and in vitro Metabolism Studies.Biomed. Chromatogr. 20: 282-293. 
[122] Novakova L, Lopez Sofia Arnal, Solichova D, Šatinsky D, Kulichova B, Horna A, Solich 
P (2009) Comparison of UV and Charged Aerosol Detection approach in 
Pharmaceutical Analysis of Statins. Talanta 78: 834-839. 
[123] Kublin E, Malanowicz E, Kaczmarska-Graczyk B, Mazurek AP (2012) Development of 
Xhromatographic Method for Determination of Drugs Reducing Cholesterol Level. Acta 
Pol. Pharm. 69: 139-143. 
[124] Gomes FP, Garcia PL, Alves JMP, Singh AK, Kedor-Hackmamm ERM, Santoro MIRM 
(2009) Development and Validation of Stability-Indicating HPLC Methods for 
Quantitaive Determination of Pravastatin, Fluvastatin, Atorvastatin and Rosuvastatin in 
Pharmaceuticals. Anal. Lett. 42: 1784-1804. 
[125] Martín J, Buchberger W, Alonso E, Himmelsbach M, Aparicio I (2011) Comparison of 
Different Extraction Methods for the Determination of Statin Drugs in Wastewater and 
River Qater by HPLC/Q-TOF-MS. Talanta. 85: 607-615.  
 
Chromatography – The Most Versatile Method of Chemical Analysis 428 
[126] Dawod M, Breadmore MC, Guijt RM, Haddad PR (2010) Strategies for the On-line 
Preconcentration and Separation of Hypolipidaemic Drugs Using Micellar 
Electrokinetic Chromatography. J. Chromatogr. A 1217: 386-393. 
[127] Damić M, Nigović B (2010) Fast Analysis of Statins in Pharmaceuticals by MEKC. 
Chromatographia 71: 233-240. 
[128] Ishihama Y, Nakamura M, Miwa T, Kajima T, Asakawa N (2002) A Rapid Method for 
pKa Determination of Drugs Using Pressure-Assisted Capillary Electrophoresis with 
Photodiode Array Detection in Drug Discovery. J. Pharm. Sci. 91: 933-942. 
